Carsten Bokemeyer
Prof. Dr. med.
Carsten Bokemeyer
  • Klinikdirektor
  • Zentrumsleiter
  • Facharzt für Innere Medizin
  • Facharzt für Hämatologie - Internistische Onkologie
  • Ärztliches Qualitätsmanagement
Arbeitsbereich

Sprachen
Deutsch (Muttersprache)
Englisch

Fachgebiete

Tätigkeitsschwerpunkte

Lebenslauf

Auszeichnungen

Mitgliedschaften

Publikationen

Zurück
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 1988
  • 1987
Vor

Current pharmacotherapy for testicular germ cell cancer
Alsdorf W, Seidel C, Bokemeyer C, Oing C
EXPERT OPIN PHARMACO. 2019;20(7):837-850.

A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells
Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M
LEUKEMIA LYMPHOMA. 2019;60(2):334-340.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
Dieckmann K, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf C, Heinzelbecker J, Heidenreich A, Cremers J, Oing C, Hermanns T, Fankhauser C, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G
J CLIN ONCOL. 2019;37(16):1412-1423.

Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia
Engel N, Schliffke S, Schüller U, Frenzel C, Bokemeyer C, Kubisch C, Lessel D
Front Oncol. 2019;9:420.

Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
Fenner M, Oing C, Dieing A, Gauler T, Oechsle K, Lorch A, Hentrich M, Kopp H, Bokemeyer C, Honecker F
J CANCER RES CLIN. 2019;145(3):717-723.

The P2-receptor-mediated Ca2+ signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension
Hennigs J, Lüneburg N, Stage A, Schmitz M, Körbelin J, Harbaum L, Matuszcak C, Mienert J, Bokemeyer C, Böger R, Kiefmann R, Klose H
PURINERG SIGNAL. 2019 [Epub ahead of print].

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib
Janjetovic S, Asemissen A, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P
TUMORI . 2019 [Epub ahead of print];300891619839473.

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Janning M, Kobus F, Babayan A, Wikman H, Velthaus J, Bergmann S, Schatz S, Falk M, Berger L, Böttcher L, Päsler S, Gorges T, O'Flaherty L, Hille C, Joosse S, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S
CANCERS. 2019;11(6):.

Personalisierte Krebstherapie 2018-Fiktion oder Wirklichkeit?
Loges S, Bokemeyer C
InFo Onkologie. 2019;21 (S1):3-5.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study
Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K
FUTURE ONCOL. 2019;15(8):897-907.

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" ( 72 h): findings from the MONITOR-GCSF study
Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I
SUPPORT CARE CANCER. 2019;27(6):2301-2312.

Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations
Oing C, Skowron M, Bokemeyer C, Nettersheim D
ANDROLOGY-US. 2019;7(4):487-497.

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
Retz M, Bedke J, Bögemann M, Grimm M, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend J
EUR J CANCER. 2019;107:37-45.

Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund
Schieferdecker A, Binder M, Weisel K, Bokemeyer C
DEUT MED WOCHENSCHR. 2019;144(14):982-989.

Positronenemissionstomographie bei Keimzelltumoren des Mannes: Einsatzmöglichkeiten und Grenzen
Schriefer P, Hartmann M, Oechsle K, Meyer C, Klutmann S, Fisch M, Bokemeyer C, Oing C
UROLOGE. 2019;58(4):418-423.

New Trisulfated Steroids from the Vietnamese Marine Sponge Halichondria vansoesti and Their PSA Expression and Glucose Uptake Inhibitory Activities
Tabakmakher K, Makarieva T, Denisenko V, Popov R, Dmitrenok P, Dyshlovoy S, Grebnev B, Bokemeyer C, von Amsberg G, Cuong N
MAR DRUGS. 2019;17(8):.

Aufbau von Strukturen zur Patientenversorgung
Velthaus J, Bokemeyer C, Loges S
InFo Onkologie. 2019;21(2):10-18.

Impact of taste and smell training on taste disorders during chemotherapy – TASTE trial
von Grundherr J, Koch B, Grimm D, Salchow J, Valentini L, Hummel T, Bokemeyer C, Stein A, Mann J
CANCER MANAG RES. 2019;11:4493—4504.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

ANN ONCOL. 2018;29(Suppl 4):iv96-iv110.

Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy
Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos I, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner J, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S
CANCER RES. 2018;78(12):3220-3232.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib
Berger L, Janning M, Velthaus J, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S
J THORAC ONCOL. 2018;13(12):e243-e246.

Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis
Bokemeyer C, Busse R, Engel J, Gebauer A, Hallek M, Heinemann V, Lüftner D, Wörmann B
ONCOL RES TREAT. 2018;41 Suppl 3:2-26.

Synthesis and anticancer activity of the derivatives of marine compound rhizochalin in castration resistant prostate cancer
Dyshlovoy S, Otte K, Tabakmakher K, Hauschild J, Makarieva T, Shubina L, Fedorov S, Bokemeyer C, Stonik V, von Amsberg G
ONCOTARGET. 2018;9(24):16962-16973.

Vorwort
Hallek M, Bokemeyer C, Lüftner D, Weissinger F
ONCOL RES TREAT. 2018;41 Suppl 3:1.

The impact of bleeding disorders on the socioeconomic status of adult patients. Results of a comparative single centre cohort study
Holstein K, von Mackensen S, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2018;38(3):150-157.

ESMO Consensus Conference on testicular germ cell cancer: past, present, and future considerations: diagnosis, treatment and follow-up
Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann K, Fizazi K, Fosså S, Germa-Lluch J, Giannatempo P, Gietema J, Gillessen S, Haugnes H, Heidenreich A, Hemminki K, Huddart R, Jewett M, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A
ANN ONCOL. 2018;29(8):1658-1686.

Apixaban for the Treatment of Chronic Disseminated Intravascular Coagulation: A Report of Two Cases
Janjetovic S, Holstein K, Dicke C, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2018 [Epub ahead of print].

Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer
Oing C, Bokemeyer C
CURR OPIN UROL. 2018;28(5):479-484.

Palliative treatment of germ cell cancer
Oing C, Giannatempo P, Honecker F, Oechsle K, Bokemeyer C, Beyer J
CANCER TREAT REV. 2018;71:102-107.

Therapeutic approaches for refractory germ cell cancer
Oing C, Seidel C, Bokemeyer C
EXPERT REV ANTICANC. 2018;18(4):389-397.

BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy
Oing C, Tennstedt P, Simon R, Volquardsen J, Borgmann K, Bokemeyer C, Petersen C, Dikomey E, Rothkamm K, Mansour W
CANCER LETT. 2018;423:60-70.

5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells
Oing C, Verem I, Mansour W, Bokemeyer C, Dyshlovoy S, Honecker F
INT J MOL SCI. 2018;20(1):21.

Treatment of Metastatic Spindle Epithelial Tumor with Thymus-Like Differentiation (SETTLE) - Long-Term Disease Control by Multimodal Therapy
Quidde J, Alsdorf W, von Amsberg G, Wilczak W, Bokemeyer C
ONCOL RES TREAT. 2018;41(1-2):58-60.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database
Salem M, Yin J, Weinberg B, Renfro L, Pederson L, Maughan T, Adams R, Van Cutsem E, Falcone A, Tebbutt N, Seymour M, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent D, Marshall J
EUR J CANCER. 2018;103:205-213.

Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients
Samsen A, von der Heyde S, Bokemeyer C, David K, Flath B, Graap M, Grebenstein B, Heflik L, Hollburg W, Layer P, von Leitner E, Overkamp F, Saeger W, Schneider S, von Seydewitz C, Stang A, Stein A, Zornig C, Juhl H
ONCOTARGET. 2018;9(78):34794-34809.

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
Schliffke S, Sivina M, Kim E, Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger J, Binder M
ONCOIMMUNOLOGY. 2018;7(4):e1417720.

Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial
Scholl I, Hahlweg P, Lindig A, Bokemeyer C, Coym A, Hanken H, Müller V, Smeets R, Witzel I, Kriston L, Härter M
IMPLEMENT SCI. 2018;13(1):51.

Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors
Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Bokemeyer C
EUR J CANCER. 2018;94:16-25.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
Sjoquist K, Renfro L, Simes R, Tebbutt N, Clarke S, Seymour M, Adams R, Maughan T, Saltz L, Goldberg R, Schmoll H, Van Cutsem E, Douillard J, Hoff P, Hecht J, Tournigand C, Punt C, Koopman M, Hurwitz H, Heinemann V, Zalcberg J
JNCI-J NATL CANCER I. 2018;110(6):638-648.

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
Stamm H, Klingler F, Grossjohann E, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W
ONCOGENE. 2018;37(39):5269-5280.

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges S
HAEMATOLOGICA. 2018;103(6):939-948.

MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphoma
Akyüz N, Albert-Konetzny N, Pott C, Callet-Bauchu E, Bokemeyer C, Murga Penas E, Dierlamm J
LEUKEMIA LYMPHOMA. 2017;58(10):2480-2484.

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker
Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford C, Asemissen A, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M
INT J CANCER. 2017;140(11):2535-2544.

Testis cancer: some problems still remain unsolved
Albers P, Bokemeyer C
WORLD J UROL. 2017;35(8):1159-1160.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia
Ben Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus J, Rankin S, Clark R, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf T, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason G, Holyoake T, Loges S
CLIN CANCER RES. 2017;23(9):2289-2300.

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study
Bokemeyer C, Gascón P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, Abraham I, MacDonald K
SUPPORT CARE CANCER. 2017;25(6):1819-1828.

Kapitel 11 - Tumore des Urogenitaltrakts
Bokemeyer C, Oing C
2017. Handbuch ONKOLOGIE 2017. 1. Aufl. Wiesbaden: med publico GmbH, 1 - 38.

Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel
Boormans J, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes M, Bokemeyer C, Nicolai N, Algaba F, Oldenburg J, Albers P
EUR UROL. 2017.

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-KPolymorphism
Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M
CANCER RES. 2017;77(5):1188-1199.

Corrigendum re: "Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours" [Eur Urol 2017;71:213-20]
Dieckmann K, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, Hammel J, Melchior S, Wosniok W, Belge G
EUR UROL. 2017;71(5):e161.

Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours
Dieckmann K, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, Hammel J, Melchior S, Wosniok W, Belge G
EUR UROL. 2017;71(2):213-220.

Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
Dulz S, Asselborn N, Dieckmann K, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger L, Alsdorf W, Mankichian B, Meyer C, Vetterlein M, Gild P, Ludwig T, Soave A, Schriefer P, Becker A, Ahyai S, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun F, Kluth L
J CANCER RES CLIN. 2017;143(7):1319-1325.

The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells
Dyshlovoy S, Madanchi R, Hauschild J, Otte K, Alsdorf W, Schumacher U, Kalinin V, Silchenko A, Avilov S, Honecker F, Stonik V, Bokemeyer C, von Amsberg G
BMC CANCER. 2017;17(1):93.

Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin
Dyshlovoy S, Otte K, Venz S, Hauschild J, Junker H, Makarieva T, Balabanov S, Alsdorf W, Madanchi R, Honecker F, Bokemeyer C, Stonik V, von Amsberg G
PROTEOMICS. 2017;17(11):.

Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells
Dyshlovoy S, Rast S, Hauschild J, Otte K, Alsdorf W, Madanchi R, Kalinin V, Silchenko A, Avilov S, Dierlamm J, Honecker F, Stonik V, Bokemeyer C, von Amsberg G
LEUKEMIA LYMPHOMA. 2017;58(12):2905-2915.

Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension
Harbaum L, Baaske K, Simon M, Oqueka T, Sinning C, Glatzel A, Lüneburg N, Sydow K, Bokemeyer C, Klose H
BMC PULM MED. 2017;17(1):72.

Specific Characteristics of Patients with Advanced Genitourinary Cancer Receiving Specialized Inpatient Palliative Care
Iversen K, Oechsle K, Oing C, Bokemeyer C, Seidel C
ONCOL RES TREAT. 2017;40(10):609-614.

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia
Latuske E, Stamm H, Klokow M, Vohwinkel G, Muschhammer J, Bokemeyer C, Jücker M, Kebenko M, Fiedler W, Wellbrock J
ONCOTARGET. 2017;8(17):29187-29201.

The Inhibitory Activity of Luzonicosides from the Starfish Echinaster luzonicus against Human Melanoma Cells
Malyarenko O, Dyshlovoy S, Kicha A, Ivanchina N, Malyarenko T, Carsten B, Gunhild v, Stonik V, Ermakova S
MAR DRUGS. 2017;15(7):.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M
HAEMATOLOGICA. 2017;102(9):e368-e370.

Self-assessment and Screening for palliative care need in patients with chronic heart failure
Oechsle K, Ehlert J, Kodolitsch Y, Ullrich A, Bokemeyer C, Rybczynski M
J PALLIAT CARE. 2017;2017(7):304.

Platinum-refractory germ cell tumors: an update on current treatment options and developments
Oing C, Alsdorf W, von Amsberg G, Oechsle K, Bokemeyer C
WORLD J UROL. 2017;35(8):1167-1175.

Immuncheckpointinhibition beim Urothelkarzinom: Pembrolizumab als neuer Therapiestandard in der Zweitlinientherapie?
Oing C, Bokemeyer C
ONKOLOGE. 2017;23:678-680.

„Neue Substanzen in der Therapie des metastasierten Nierenzellkarzinoms – was, wann und für wen?“: Neuer Tyrosinkinaseinhibitor für die Zweitlinie
Oing C, Bokemeyer C
InFo Onkologie. 2017;03:12-14.

Neues zum Einsatz von Tumormarkern bei Hodentumoren: Inadäquater Markerabfall und miR-371a-3p
Oing C, Bokemeyer C
LEADING OPINIONS Hämatologie & Onkologie. 2017;13(7):14-15.

Monoubiquitination of histone H2B – a potential new target in treatment resistant germ cell tumors.
Oing C, Dyshlovoy S, Burandt E, Amsberg G, Honecker F, Bokemeyer C, Rothkamm K, Mansour W
ONCOL RES TREAT. 2017;40:95-96.

Impact of Primary Metastatic Bone Disease in Germ Cell Tumors: Results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study
Oing C, Oechsle K, Necchi A, Loriot Y, De Giorgi U, Fléchon A, Daugaard G, Fedyanin M, Faré E, Bokemeyer C
ANN ONCOL. 2017;28(3):576-582.

Cisplatin-refraktäre Keimzelltumoren: Resistenzmechanismen − Therapiestandards − neue Entwicklungen
Oing C, Seidel C, Alsdorf W, Bokemeyer C
ONKOLOGE. 2017;23(2):123-128.

Systemische Behandlung des Harnblasenkarzinoms: Klassische Chemotherapie und neue Optionen
Oing C, von Amsberg G, Bokemeyer C
Im Focus Onkologie. 2017;20(9):50-56.

Versorgung von Patienten nach Krebserkrankung im Kindes-, Jugend- oder jungen Erwachsenenalter
Quidde J, Koch B, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
J Onkol - Z Onkol Fortb. 2017;2017(10):862-866.

Das CARE-for-CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2017;32(06):479-484.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database
Renfro L, Goldberg R, Grothey A, Sobrero A, Adams R, Seymour M, Heinemann V, Schmoll H, Douillard J, Hurwitz H, Fuchs C, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff P, Kabbinavar F, Falcone A, Tebbutt N, Punt C, Hecht J, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent D
J CLIN ONCOL. 2017;35(17):1929-1937.

Mutational landscape reflects the biological continuum of plasma cell dyscrasias
Rossi A, Voigtländer M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder M
BLOOD CANCER J. 2017;7(2):e537.

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis
Thoennissen G, Görlich D, Bacher U, Aufenberg T, Hüsken A, Hansmeier A, Evers G, Mikesch J, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters R, Krug U, Kropff M, Thoennissen N, Berdel W
ACTA HAEMATOL-BASEL. 2017;137(3):163-172.

The effects of music therapy in patients with high-dose chemotherapy and stem cell support: a randomized pilot study
Tuinmann G, Preissler P, Böhmer H, Suling A, Bokemeyer C
PSYCHO-ONCOLOGY. 2017;26(3):377-384.

Quality of life, psychological burden, needs, and satisfaction during specialized inpatient palliative care in family caregivers of advanced cancer patients
Ullrich A, Ascherfeld L, Marx G, Bokemeyer C, Bergelt C, Oechsle K
BMC PALLIAT CARE. 2017;16(1):31.

Neue Aspekte in der Therapie des metastasierten Prostatakarzinoms
von Amsberg G, Bokemeyer C
DEUT MED WOCHENSCHR. 2017;142(15):1106-1110.

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S
NAT COMMUN. 2017;8(1):269.

Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)
Aapro M, Bokemeyer C, Ludwig H, Gascón P, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, MacDonald K, Abraham I
J GERIATR ONCOL. 2016;8(2):86-95.

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
Aapro M, Ludwig H, Bokemeyer C, Gascón P, Boccadoro M, Denhaerynck K, Krendyukov A, Gorray M, MacDonald K, Abraham I
ANN ONCOL. 2016;27(11):2039-2045.

EAU Guidelines on Testicular Cancer - 2016 edition
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M, Nicolai N, Oldenburg J
2016.

Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature
Alsdorf W, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, Binder M
J Oncol Pharm Pract. 2016;22(3):523-7.

Lieferengpässe von Onkologika: Die gesicherte Versorgung ist ethische Verpflichtung
Bokemeyer C
Perspektiven der Onkologie. 2016;(2):28-29.

Sekundärneoplasien nach Primärtherapie als besondere Belastung von Krebspatienten
Bokemeyer C
2016. Handbuch Psychoonkologie. Mehnert A, Koch U (Hrsg.). 1. Aufl. Hogrefe, 77-86.

Vorwort
Bokemeyer C, Hallek M, Lüftner D, Weißinger F
ONCOL RES TREAT. 2016;39 Suppl 2(Suppl 2):1.

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
Braig F, Voigtländer M, Schieferdecker A, Busch C, Laban S, Grob T, Kriegs M, Knecht R, Bokemeyer C, Binder M
ONCOTARGET. 2016;7(28):42988-42995.

Cyclin D1 gene amplification is highly homogeneous in breast cancer
Burandt E, Grünert M, Lebeau A, Choschzick M, Quaas A, Jänicke F, Müller V, Scholz U, Bokemeyer C, Petersen C, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Wilczak W
BREAST CANCER-TOKYO. 2016;23(1):111-9.

Corrigendum to 'Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer", [Thromb. Res. 141 (2016) 39-48]
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;146:135.

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;141:39-48.

Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Degwert N, Latuske E, Vohwinkel G, Stamm H, Klokow M, Bokemeyer C, Fiedler W, Wellbrock J
EUR J HAEMATOL. 2016;97(3):239-44.

Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias
Dicke C, Schneppenheim S, Holstein K, Spath B, Bokemeyer C, Dittmer R, Budde U, Langer F
ANN HEMATOL. 2016;95(6):945-57.

The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer
Dyshlovoy S, Menchinskaya E, Venz S, Rast S, Amann K, Hauschild J, Otte K, Kalinin V, Silchenko A, Avilov S, Alsdorf W, Madanchi R, Bokemeyer C, Schumacher U, Walther R, Aminin D, Fedorov S, Shubina L, Stonik V, Balabanov S, Honecker F, von Amsberg G
INT J CANCER. 2016;138(10):2450-65.

Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer
Dyshlovoy S, Otte K, Alsdorf W, Hauschild J, Lange T, Venz S, Bauer C, Bähring R, Amann K, Mandanchi R, Schumacher U, Schröder-Schwarz J, Makarieva T, Guzii A, Tabakmakher K, Fedorov S, Shubina L, Kasheverov I, Ehmke H, Steuber T, Stonik V, Bokemeyer C, Honecker F, von Amsberg G
ONCOTARGET. 2016;7(43):69703 - 69717.

Guanidine Alkaloids from the Marine Sponge Monanchora pulchra Show Cytotoxic Properties and Prevent EGF-Induced Neoplastic Transformation in Vitro
Dyshlovoy S, Tabakmakher K, Hauschild J, Shchekaleva R, Otte K, Guzii A, Makarieva T, Kudryashova E, Fedorov S, Shubina L, Bokemeyer C, Honecker F, Stonik V, von Amsberg G
MAR DRUGS. 2016;14(7):E133.

Anti-migratory activity of marine alkaloid monanchocidin A - proteomics-based discovery and confirmation
Dyshlovoy S, Venz S, Hauschild J, Tabakmakher K, Otte K, Madanchi R, Walther R, Guzii A, Makarieva T, Shubina L, Fedorov S, Stonik V, Bokemeyer C, Balabanov S, Honecker F, von Amsberg G
PROTEOMICS. 2016;16(10):1590-603.

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group
Feldman D, Lorch A, Kramar A, Albany C, Einhorn L, Giannatempo P, Necchi A, Flechon A, Boyle H, Chung P, Huddart R, Bokemeyer C, Tryakin A, Sava T, Winquist E, De Giorgi U, Aparicio J, Sweeney C, Cohn Cedermark G, Beyer J, Powles T
J CLIN ONCOL. 2016;34(4):345-51.

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
Gascón P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K, Abraham I
SUPPORT CARE CANCER. 2016;24(2):911-25.

Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells
Gerwing M, Jacobsen C, Dyshlovoy S, Hauschild J, Rohlfing T, Oing C, Venz S, Oldenburg J, Oechsle K, Bokemeyer C, von Amsberg G, Honecker F
J CANCER RES CLIN. 2016;142(9):1979-94.

Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension
Harbaum L, Renk E, Yousef S, Glatzel A, Lüneburg N, Hennigs J, Oqueka T, Baumann H, Atanackovic D, Grünig E, Böger R, Bokemeyer C, Klose H
BMC PULM MED. 2016;16(1):145.

Lieferengpässe in der Onkologie: Frühzeitige und verpflichtende Meldung gefordert
Hofmann-Aßmus M, Bokemeyer C
Onkologie heute. 2016;15(8):46-47.

The impact of social factors on outcomes in patients with bleeding disorders
Holstein K, von Mackensen S, Bokemeyer C, Langer F
HAEMOPHILIA. 2016;22(1):46-53.

Hodgkin's lymphoma as a rare variant of Richter's transformation in chronic lymphocytic leukemia: A case report and review of the literature
Janjetovic S, Bernd H, Bokemeyer C, Fiedler W
Mol Clin Oncol. 2016;4(3):390-392.

The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus
Kilic E, Tennstedt P, Högner A, Lebok P, Sauter G, Bokemeyer C, Izbicki J, Wilczak W
VIRCHOWS ARCH. 2016;468(4):483-92.

Prospective Study on Music Therapy in Terminally Ill Cancer Patients during Specialized Inpatient Palliative Care
Kordovan S, Preissler P, Kamphausen A, Bokemeyer C, Oechsle K
J PALLIAT MED. 2016;19(4):394-9.

Keimzelltumoren des Mannes
Lorch A, Albers P, Beyer J, Cathomas R, Oing C, Souchon R, Stöger H, Bokemeyer C
2016.

High Ki67 expression is an independent good prognostic marker in colorectal cancer
Melling N, Kowitz C, Simon R, Bokemeyer C, Terracciano L, Sauter G, Izbicki J, Marx A
J CLIN PATHOL. 2016;69(3):209-14.

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger L, Oechsle K, Schumacher K, Kanfer E, Bourhis J, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F
BONE MARROW TRANSPL. 2016;51(3):384-90.

Investigational targeted therapies for the treatment of testicular germ cell tumors
Oing C, Kollmannsberger C, Oechsle K, Bokemeyer C
EXPERT OPIN INV DRUG. 2016;25(9):1033-43.

PARP-Inhibition - eine neue Therapieoption bei Prostatakarzinomen mit DNA-Reparaturdefizienz
Oing C, Mansour W, Bokemeyer C
InFo Onkologie. 2016;(02):2-3.

Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature
Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C
J UROLOGY. 2016;195(2):254-63.

Pharmacotherapeutic treatment of germ cell tumors - standard of care and recent developments
Oing C, Seidel C, von Amsberg G, Oechsle K, Bokemeyer C
EXPERT OPIN PHARMACO. 2016;17(4):545-60.

Detrimental social interactions predict loss of dignity among patients with cancer
Philipp R, Mehnert A, Lehmann C, Oechsle K, Bokemeyer C, Krüll A, Vehling S
SUPPORT CARE CANCER. 2016;24(6):2751-8.

Musiktherapie auf der Palliativstation: Ergebnisse einer Studie über ein musiktherapeutisches Angebot
Preissler P, Kordovan S, Bokemeyer C, Oechsle K
Musiktherapeutische Umschau. 2016;37(3):233-249.

Favored subjects and psychosocial needs in music therapy in terminally ill cancer patients: a content analysis
Preissler P, Kordovan S, Ullrich A, Bokemeyer C, Oechsle K
BMC PALLIAT CARE. 2016;15:48.

Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature
Quidde J, Azémar M, Bokemeyer C, Arnold D, Stein A
Ther Adv Med Oncol. 2016;8(3):144-52.

Improved nutrition in adolescents and young adults after childhood cancer - INAYA study
Quidde J, von Grundherr J, Koch B, Bokemeyer C, Escherich G, Valentini L, Buchholz D, Schilling G, Stein A
BMC CANCER. 2016;16(1):872.

Testicular germ cell tumours
Rajpert-De Meyts E, McGlynn K, Okamoto K, Jewett M, Bokemeyer C
LANCET. 2016;387(10029):1762-74.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database
Renfro L, Loupakis F, Adams R, Seymour M, Heinemann V, Schmoll H, Douillard J, Hurwitz H, Fuchs C, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt N, Punt C, Hecht J, Bokemeyer C, Van Cutsem E, Goldberg R, Saltz L, de Gramont A, Sargent D, Lenz H
J CLIN ONCOL. 2016;34(2):144-150.

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, Pein U, Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M
BLOOD. 2016;127(25):3202-14.

Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia
Schliffke S, Akyüz N, Ford C, Mährle T, Thenhausen T, Krohn-Grimberghe A, Knop S, Bokemeyer C, Binder M
LEUKEMIA. 2016;30(11):2232-2234.

Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care-Registry data from an outcomes research project of the German Testicular Cancer Study Group
Seidel C, Oechsle K, Lorch A, Dieing A, Hentrich M, Hornig M, Grünwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C
UROL ONCOL-SEMIN ORI. 2016;34(4):167.e21-8.

Expression and release of platelet protein disulphide isomerase in patients with haemophilia A
Voigtländer M, Holstein K, Spath B, Bokemeyer C, Langer F
HAEMOPHILIA. 2016;22(6):e537-e544.

Fortschritte in der Therapie urogenitaler Tumoren
von Amsberg G, Bokemeyer C
Im Focus Onkologie. 2016;19(7-8):64.

Pretrichodermamides D-F from a Marine Algicolous Fungus Penicillium sp. KMM 4672
Yurchenko A, Smetanina O, Ivanets E, Kalinovsky A, Khudyakova Y, Kirichuk N, Popov R, Bokemeyer C, von Amsberg G, Chingizova E, Afiyatullov S, Dyshlovoy S
MAR DRUGS. 2016;14(7):E122.

eau Guidelines on Testicular Cancer
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M, Nicolai N, Oldenburg J
2015. eau Guidelines on Testicular Cancer. 1-48.

Guidelines on Testicular Cancer: 2015 Update
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M, Nicolai N, Oldenburg J
EUR UROL. 2015;68(6):1054-68.

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger J, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer C, Loges S
ONCOTARGET. 2015;6(8):6341-58.

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
Bokemeyer C, Köhne C, Ciardiello F, Lenz H, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken J, Tejpar S
EUR J CANCER. 2015;51(10):1243-52.

Tumore des Urogenitaltrakts
Bokemeyer C, Oing C
2015. OnkoUpdate 2015. 1. Aufl. med publico GmbH, 1-55.

Metastatic Germ Cell Cancer: The Intermediate-Prognosis Risk Category
Bokemeyer C, Seidel C
2015. Diagnosis and Management of Testicular Cancer. Krege S (Hrsg.). 1. Aufl. Springer, 55-64.

A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer
Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C
GASTRIC CANCER. 2015;18(4):833-842.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M
ONCOTARGET. 2015;6(14):12035-47.

PD-1 Blockade zeigt therapeutische Aktivität: Neuer Therapieansatz beim rezidiveren Hodgkin-Lymphom
Coym A, Dierlamm J, Bokemeyer C
InFo Onkologie. 2015;(6):34-36.

The Rare Occurrence of the Translocation t(8;14) in Chronic Lymphatic Leukemia: Case Report and Review of the Literature
Coym A, Janjetovic S, Bokemeyer C, Fiedler W
Ann Hematol Oncol. 2015;2(5):1039.

Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study
Dicke C, Amirkhosravi A, Spath B, Jiménez-Alcázar M, Fuchs T, Davila M, Francis J, Bokemeyer C, Langer F
Exp Hematol Oncol. 2015;4:22.

Atypical venous thromboses in myeloproliferative neoplasias
Dicke C, Frölich A, Holstein K, Bokemeyer C, Langer F
PHLEBOLOGIE. 2015;44(6):324–329.

Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization
Dyshlovoy S, Hauschild J, Amann K, Tabakmakher K, Venz S, Walther R, Guzii A, Makarieva T, Shubina L, Fedorov S, Stonik V, Bokemeyer C, Balabanov S, Honecker F, Amsberg G
ONCOTARGET. 2015;6(19):17328-41.

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
Élez E, Kocáková I, Höhler T, Martens U, Bokemeyer C, Van Cutsem E, Melichar B, Smakal M, Csőszi T, Topuzov E, Orlova R, Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J
ANN ONCOL. 2015;26(1):132-40.

Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
Gascón P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K, Abraham I
SUPPORT CARE CANCER. 2015;24(2):927.

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller M, Hehlmann R, Hofmann W, Fabarius A, Seifarth W
PLOS ONE. 2015;10(6):e0129648.

High intratumoral FOXP3⁺ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer
Hanke T, Melling N, Simon R, Sauter G, Bokemeyer C, Lebok P, Terracciano L, Izbicki J, Marx A
AM J CLIN PATHOL. 2015;8(7):8227-35.

Peritumoral eosinophils predict recurrence in colorectal cancer
Harbaum L, Pollheimer M, Kornprat P, Lindtner R, Bokemeyer C, Langner C
MODERN PATHOL. 2015;28(3):403-13.

Age-related variation and predictors of long-term quality of life in germ cell tumor survivors
Hartung T, Mehnert A, Friedrich M, Hartmann M, Vehling S, Bokemeyer C, Oechsle K
UROL ONCOL-SEMIN ORI. 2015.

Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy
Jacobsen C, Oechsle K, Hauschild J, Steinemann G, Spath B, Bokemeyer C, Ruf W, Honecker F, Langer F
THROMB RES. 2015;136(3):673-81.

Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT
Karagiannis P, Guth N, Thoennissen G, Bern C, Sperveslage J, Oschlies I, Bokemeyer C, Klapper W, Wardelmann E, Thoennissen N
Clin Sarcoma Res. 2015;5:24.

ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts
Kebenko M, Drenckhan A, Gros S, Jücker M, Grabinski N, Ewald F, Grottke A, Schultze A, Izbicki J, Bokemeyer C, Wellbrock J, Fiedler W
CELL SIGNAL. 2015;27(2):373-81.

Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers
Melling N, Grimm N, Simon R, Stahl P, Bokemeyer C, Terracciano L, Sauter G, Izbicki J, Marx A
PATHOL ONCOL RES. 2015;22(1):95-102.

Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer
Melling N, Muth J, Simon R, Bokemeyer C, Terracciano L, Sauter G, Izbicki J, Marx A
DIAGN PATHOL. 2015;10:125.

Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization
Melling N, Simon R, Izbicki J, Terracciano L, Bokemeyer C, Sauter G, Marx A
AM J CLIN PATHOL. 2015;8(6):7009-15.

Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer
Melling N, Simon R, Mirlacher M, Izbicki J, Stahl P, Terracciano L, Bokemeyer C, Sauter G, Marx A
HISTOPATHOLOGY. 2015;68(2):191-8.

The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis
Nickel K, Ronquist G, Langer F, Labberton L, Fuchs T, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou E, Ronquist G, Renné T
BLOOD. 2015;126(11):1379-89.

Symptom burden in long-term germ cell tumor survivors
Oechsle K, Hartmann M, Mehnert A, Oing C, Bokemeyer C, Vehling S
SUPPORT CARE CANCER. 2015.

First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database
Oing C, Lorch A, Bokemeyer C, Honecker F, Beyer J, Berger L, Oechsle K
J CANCER RES CLIN. 2015;141(5):923-31.

Biological Relevance and Therapeutic Potential of the Hypusine Modification System
Pallmann N, Braig M, Sievert H, Preukschas M, Hermans-Borgmeyer I, Schweizer M, Nagel C, Neumann M, Wild P, Haralambieva E, Hagel C, Bokemeyer C, Hauber J, Balabanov S
J BIOL CHEM. 2015;290(30):18343-18360.

Anxiety and fear of cancer recurrence and its association with supportive care needs and health-care service utilization in cancer patients
Sarkar S, Sautier L, Schilling G, Bokemeyer C, Koch-Gromus U, Mehnert A
J CANCER SURVIV. 2015;9(4):567-575.

Thrombin generation in a patient with an acquired high-titre factor V inhibitor
Schmidt D, Steinhagen F, Schnabel C, Spath B, Holstein K, Fiedler W, Bokemeyer C, Renné T, Langer F
BLOOD COAGUL FIBRIN. 2015;26(1):81-87.

Integration von palliativmedizinischer Betreuung – Ist früher besser?
Schmitz M, Bokemeyer C, Oechsle K
ONKOLOGE. 2015;21(1):848-851.

Needs, symptoms, and outcome of patients with advanced head and neck cancer treated on a palliative care inpatient ward
Schmitz M, Wolfram M, Bokemeyer C, Oechsle K
2015. Gemeinsame Jahrestagung, Basel, Oktober 2015: Abstracts. .

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database
Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll H, Seymour M, Adams R, Saltz L, Goldberg R, Punt C, Douillard J, Hoff P, Hecht J, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt N, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar F, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent D
J CLIN ONCOL. 2015;33(1):22-8.

Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer
Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki J, Bokemeyer C, Simon R, Sauter G, Marx A
BMC GASTROENTEROL. 2015;15(1):7.

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
Stein A, Atanackovic D, Hildebrandt B, Stübs P, Brugger W, Hapke G, Steffens C, Illerhaus G, Bluemner E, Stöhlmacher J, Bokemeyer C
BRIT J CANCER. 2015;113(6):872-7.

Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers
Ummanni R, Duscharla D, Barett C, Venz S, Schlomm T, Heinzer H, Walther R, Bokemeyer C, Brümmendorf T, Murthy P, Balabanov S
J PROTEOMICS. 2015;119:218-29.

The Preference to Discuss Expected Survival Is Associated with Loss of Meaning and Purpose in Terminally Ill Cancer Patients
Vehling S, Kamphausen A, Oechsle K, Hroch S, Bokemeyer C, Mehnert A
J PALLIAT MED. 2015;18(11):970-976.

Anxiety and depression in long-term testicular germ cell tumor survivors
Vehling S, Mehnert A, Hartmann M, Oing C, Bokemeyer C, Oechsle K
GEN HOSP PSYCHIAT. 2015.

Clinical Evidence that Coagulation Activation Drives Cancer Progression - a Report of 2 Cases
Voigtländer M, Holstein K, Leuenroth S, Mudter J, Bokemeyer C, Langer F
ONCOL RES TREAT. 2015;38(9):449-52.

Hospital population screening reveals overrepresentation of CD5(-) monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type
Voigtländer M, Vogler B, Trepel M, Panse J, Jung R, Bokemeyer C, Bacher U, Binder M
ANN HEMATOL. 2015;94(9):1559-65.

Viele innovative Substanzen: Kastrationsresistentes fortgeschrittenes Prostatakarzinom
von Amsberg G, Steuber T, Bokemeyer C
Deut Arzteblatt. 2015;112(20):8-10.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension
Wellbrock J, Harbaum L, Stamm H, Hennigs J, Schulz B, Klose H, Bokemeyer C, Fiedler W, Lüneburg N
LUNG. 2015.

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Wellbrock J, Latuske E, Köhler J, Wagner K, Stamm H, Vettorazzi E, Vohwinkel G, Klokow M, Uibeleisen R, Ehm P, Riecken K, Loges S, Thol F, Schubert C, Amling M, Jücker M, Bokemeyer C, Heuser M, Krauter J, Fiedler W
CLIN CANCER RES. 2015.

Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom
Amsberg G, Strölin P, Bokemeyer C, Steuber T
DEUT MED WOCHENSCHR. 2014;139(41):2086-90.

First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)
Berger L, Bokemeyer C, Lorch A, Hentrich M, Kopp H, Gauler T, Beyer J, de Wit M, Mayer F, Boehlke I, Oing C, Honecker F, Oechsle K
J CANCER RES CLIN. 2014;140(7):1211-1220.

Nicotinamide treatment ameliorates the course of experimental colitis mediated by enhanced neutrophil-specific antibacterial clearance
Bettenworth D, Nowacki T, Ross M, Kyme P, Schwammbach D, Kerstiens L, Thoennissen G, Bokemeyer C, Hengst K, Berdel W, Heidemann J, Thoennissen N
MOL NUTR FOOD RES. 2014;58(7):1474-1490.

Editorial. Cancer Survivorship
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:157.

Editorial. Guten Appetit - Mythen und Fakten zur Ernährung bei Krebspatienten
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:361.

Editorial. Im stetigen Wandel
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:457.

Editorial. Innovation und Zukunft
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:261.

Editorial. Komplexes Wechselspiel
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:77.

Editorial. Schritt für Schritt
Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29(1):1.

Nausea und Emesis bei urogenitalen Tumoren
Bokemeyer C
2014. Nausea und Emesis in der Onkologie. Lordick F, Lorenzen S (Hrsg.). 1. Aufl. Uni-Med, 86-96.

Studien sind Teil der Behandlung
Bokemeyer C
Hilfe! Zwischen Krankheit, Versorgung und Geschäft. Ein Magazin im Auftrag des BPI . 2014;20-21.

Prostatakarzinom
Bokemeyer C, Heidenreich A, Schaefer R
2014. Krebsfrüherkennung in Deutschland 2014. Freund M, Lüftner D, Wilhelm M (Hrsg.). 1. Aufl. 79-91.

Moderne Krebstherapie: aktueller Stand und zukünftige Entwicklung
Bokemeyer C, Hiddemann W
DEUT MED WOCHENSCHR. 2014;139(41):2067.

Tumore des Urogenitaltrakts
Bokemeyer C, Oing C
2014. OnkoUpdate 2014. 1. Aufl. med publico GmbH, 1-40.

A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells
Braig M, Pällmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph K, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, Brümmendorf T
LEUKEMIA. 2014;28(10):2028-39.

Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice
Burandt E, Schreiber M, Stein A, Minner S, Clauditz T, Bokemeyer C, Jänicke F, Fisch M, Izbicki J, Knecht R, Sauter G, Stahl P
GENE CHROMOSOME CANC. 2014;53(3):228-39.

Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus
Dicke C, Holstein K, Schneppenheim S, Dittmer R, Schneppenheim R, Bokemeyer C, Iking-Konert C, Budde U, Langer F
Exp Hematol Oncol. 2014;3:21.

Aaptamines from the marine sponge Aaptos sp. display anticancer activities in human cancer cell lines and modulate AP-1-, NF-κB-, and p53-dependent transcriptional activity in mouse JB6 Cl41 cells
Dyshlovoy S, Fedorov S, Shubina L, Kuzmich A, Bokemeyer C, Amsberg G, Honecker F
BIOMED RES INT . 2014;2014:469309.

Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancer
Dyshlovoy S, Venz S, Shubina L, Fedorov S, Walther R, Jacobsen C, Stonik V, Bokemeyer C, Balabanov S, Honecker F
J PROTEOMICS. 2014;96:223-39.

Akute myeloische Leukämie –bestmögliche Behandlung.
Fiedler W, Janning M, Kebenko M, Weidmann J, Janjetovic S, Bokemeyer C
Hamb Ärztebl. 2014;68:11-17.

Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance
Flammiger A, Bacher U, Christopeit M, Horn C, Rühlmann E, Kluge K, Vettorazzi E, Bokemeyer C, Binder M
LEUKEMIA LYMPHOMA. 2014;56(3):639-644.

Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy
Harbaum L, Hennigs J, Baumann H, Bokemeyer C, Olschewski H, Klose H
EUR RESPIR J. 2014;43(5):1513-5.

N-terminal pro-brain natriuretic Peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency
Harbaum L, Hennigs J, Baumann H, Lüneburg N, Griesch E, Bokemeyer C, Grünig E, Klose H
PLOS ONE. 2014;9(4):e94263.

The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study
Heiss M, Ströhlein M, Bokemeyer C, Arnold D, Parsons S, Seimetz D, Lindhofer H, Schulze E, Hennig M
CLIN CANCER RES. 2014;20(12):3348-57.

Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse
Hennigs J, Müller J, Adam M, Spin J, Riedel E, Graefen M, Bokemeyer C, Sauter G, Huland H, Schlomm T, Minner S
PLOS ONE. 2014;9(7):e100469.

Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor
Holstein K, Schneppenheim R, Schrum J, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2014;34 (4A):5-8.

Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines
Honecker F, Rohlfing T, Harder S, Braig M, Gillis A, Gläsener S, Barett C, Bokemeyer C, Buck F, Brümmendorf T, Looijenga L, Balabanov S
J PROTEOMICS. 2014;96:300-13.

Exercise training in patients with advanced gastrointestinal cancer undergoing palliative chemotherapy: a pilot study
Jensen W, Baumann F, Stein A, Bloch W, Bokemeyer C, de Wit M, Oechsle K
SUPPORT CARE CANCER. 2014;22(7):1797-806.

Physical exercise and therapy in terminally ill cancer patients: a retrospective feasibility analysis
Jensen W, Bialy L, Ketels G, Baumann F, Bokemeyer C, Oechsle K
SUPPORT CARE CANCER. 2014;22(5):1261-8.

Effects of exercise training programs on physical performance and quality of life in patients with metastatic lung cancer undergoing palliative chemotherapy--a study protocol
Jensen W, Oechsle K, Baumann H, Mehnert A, Klose H, Bloch W, Bokemeyer C, Baumann F
CONTEMP CLIN TRIALS. 2014;37(1):120-8.

Therapie von Kopf-Hals-Karzinomen
Knecht R, Busch C, Lörincz B, Schafhausen P, Tribius S, Heiland M, Jenckel F, Münscher A, Petersen C, Bokemeyer C
Hamb Ärztebl. 2014;8:12-17.

Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion
Langer F, Obser T, Oyen F, Spath B, Holstein K, Greinacher A, White J, Budde U, Bokemeyer C, Schneppenheim R
THROMB HAEMOSTASIS. 2014;111(4):777-779.

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood T, Osterborg A, Rzychon B, Mitchell D, Beguin Y
SUPPORT CARE CANCER. 2014.

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation
Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels B, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
CANCER IMMUNOL IMMUN. 2014;63(11):1151-62.

Das Handbuch gegen Krebs
Majorczyk S
2014. Das Handbuch gegen Krebs. 1. Aufl. ZS Verlag Zabert Sandmann GmbH, 1-400.

Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples
Murga-Penas E, Schilling G, Behrmann P, Klokow M, Vettorazzi E, Bokemeyer C, Dierlamm J
GENE CHROMOSOME CANC. 2014;53(6):497-515.

Circulating tumor cells in patients with testicular germ cell tumors
Nastały P, Ruf C, Becker P, Bednarz-Knoll N, Stoupiec M, Kavsur R, Isbarn H, Matthies C, Wagner W, Höppner D, Fisch M, Bokemeyer C, Ahyai S, Honecker F, Riethdorf S, Pantel K
CLIN CANCER RES. 2014;20(14):3830-41.

Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines
Nitsch E, Mina S, Brammer I, Pace A, Schuch G, Bokemeyer C, Zander A, Kröger N, Ayuketang F
ANTICANCER RES. 2014;34(4):1779-84.

Multimodal exercise training during myeloablative chemotherapy: a prospective randomized pilot trial
Oechsle K, Aslan Z, Suesse Y, Jensen W, Bokemeyer C, de Wit M
SUPPORT CARE CANCER. 2014;22(1):63-9.

Relationship Between Symptom Burden, Distress, and Sense of Dignity in Terminally Ill Cancer Patients
Oechsle K, Wais M, Vehling S, Bokemeyer C, Mehnert A
J PAIN SYMPTOM MANAG. 2014.

Testicular Germ Cell Tumors
Oing C, Bokemeyer C, Oechsle K
2014. Nuclear Oncology. 1. Aufl. Philadelphia, PA 19103 USA: Wolters Kluwer, 241-250.

Nodal, pulmonary and pleural gliomatosis in a 42-year-old-male with non-seminomatous testicular germ cell cancer
Oing C, Wagner R, Bokemeyer C, Honecker F
HISTOPATHOLOGY. 2014;65(1):142-3.

Quinone-carbohydrate nonglucoside conjugates as a new type of cytotoxic agents: synthesis and determination of in vitro activity
Pelageev D, Dyshlovoy S, Pokhilo N, Denisenko V, Borisova K, Amsberg G, Bokemeyer C, Fedorov S, Honecker F, Anufriev V
EUR J MED CHEM. 2014;77:139-44.

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Proetel U, Pletsch N, Lauseker M, Müller M, Hanfstein B, Krause S, Kalmanti L, Schreiber A, Heim D, Baerlocher G, Hofmann W, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S
ANN HEMATOL. 2014;93(7):1167-76.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M
ONCOTARGET. 2014;5(16):6647-53.

Survivorship-Programme: Ziele und Inhalte einer strukturierten Betreuung
Schilling G, Stein A, Quidde J, Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;3(29):202-205.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Trédan O, Tournigand C, Colombo N, Dudnichenko A, Westermann A, Friccius-Quecke H, Lordick F
MED ONCOL. 2014;31(8):76.

A novel mouse model for inhibition of DOHH mediated hypusine modification reveals crucial function for embryonic development, proliferation and oncogenic transformation
Sievert H, Pällmann N, Miller K, Hermans-Borgmeyer I, Venz S, Sendoel A, Preukschas M, Schweizer M, Böttcher S, Janiesch P, Streichert T, Walther R, Hengartner M, Manz M, Brümmendorf T, Bokemeyer C, Balabanov M, Hauber J, Duncan K, Balabanov S
DIS MODEL MECH. 2014.

How to select the optimal treatment for first line metastatic colorectal cancer
Stein A, Bokemeyer C
WORLD J GASTROENTERO. 2014;20(4):899-907.

Neue Substanzen für die Therapie solider Tumoren
Stein A, Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;29:300-4.

55-jährige Patientin, Raucherin, mit deutlicher Abgeschlagenheit, Fieber und Hämoptysen
Thoennissen N, Clauditz T, Ittrich H, Stahl R, Bokemeyer C, Klose H
DEUT MED WOCHENSCHR. 2014;139(41):2073-4.

Overexpression of Gremlin-1 in Patients with Loeys-Dietz Syndrome: Implications on Pathophysiology and Early Disease Detection
Wellbrock J, Sheikhzadeh S, Oliveira Ferrer L, Stamm H, Hillebrand M, Keyser B, Klokow M, Vohwinkel G, Bonk V, Otto B, Streichert T, Balabanov S, Hagel C, Rybczynski M, Bentzien F, Bokemeyer C, Kodolitsch Y, Fiedler W
PLOS ONE. 2014;9(8):e104742.

Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study
Abraham I, MacDonald K, Tharmarajah S, Bokemeyer C, Ludwig H, Soubeyran P, Battistel V, Aapro M
J GERIATR ONCOL. 2013;4(2):196-201.

The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Al-Batran S, Pauligk C, Homann N, Hartmann J, Moehler M, Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, Bokemeyer C, Mahlberg R, Hofheinz R, Luley K, Kullmann F, Jäger E
EUR J CANCER. 2013;49(4):835-842.

Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders
Atanackovic D, Nowottne U, Freier E, Weber C, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kröger N, Brunner-Weinzierl M, Bokemeyer C, Deter H
STRESS. 2013;16(4):421-8.

The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting
Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki J, Bokemeyer C
HUM VACC IMMUNOTHER . 2013;9(12):2533-42.

Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors
Balabanov S, Wilhelm T, Venz S, Amsberg G, Scharf C, Pospisil H, Balabanov M, Barett C, Bokemeyer C, Walther R, Brümmendorf T, Schuppert A
PLOS ONE. 2013;8(1):e53668.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives
Berger L, Riesenberg H, Bokemeyer C, Atanackovic D
LUNG CANCER. 2013;80(3):242-8.

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.
Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke N, Claßen J, Cohn-Cedermark G, Dahl A, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann K, Fenner M, Fizazi K, Flechon A, Fossa S, Germá Lluch J, Gietema J, Gillessen S, Giwercman A, Hartmann J, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart R, Kliesch S, Kollmannsberger C, Krege S, Laguna M, Looijenga L, Lorch A, Lotz J, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis J, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C
ANN ONCOL. 2013;24(4):878-888.

Cytogenetics of extramedullary manifestations in multiple myeloma
Billecke L, Murga Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann H, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G
BRIT J HAEMATOL. 2013;161(1):87-94.

Tumore des Urogenitaltrakts
Bokemeyer C, Oechsle K, Oing C
2013. OnkoUpDate. Wiesbaden: med publico GmbH, .

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
Christopeit M, Heiland A, Binder M, Zabelina T, Ayuketang F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(9):1257-9.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuketang F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(3):465-6.

Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?
Clauditz T, Gontarewicz A, Bokemeyer C, Sauter G, Knecht R, Münscher A, Wilczak W
J ORAL PATHOL MED. 2013;42(10):769-73.

Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment
de Wit M, Ortner P, Lipp H, Sehouli J, Untch M, Ruhnke M, Mayer-Steinacker R, Bokemeyer C, Jordan K
ONKOLOGIE. 2013;36(3):127-35.

High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M
EUR J CANCER. 2013;49(6):1273-9.

Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer
Grob T, Hoenig T, Clauditz T, Atanackovic D, Koenig A, Vashist Y, Klose H, Simon R, Pantel K, Izbicki J, Bokemeyer C, Sauter G, Wilczak W
LUNG CANCER. 2013;79(3):221-7.

A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas
Hartmann J, Horger M, Kluba T, Königsrainer A, de Zwart P, von Weyhern C, Eckert F, Budach W, Bokemeyer C
INVEST NEW DRUG. 2013;31(6):1592-601.

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Hartmann J, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm M, Heeger S, Bokemeyer C
INVEST NEW DRUG. 2013;31(3):661-668.

Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Heidenreich A, Scholz H, Rogenhofer S, Arsov C, Retz M, Müller S, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D
EUR UROL. 2013;63(6):977-982.

Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy
Honecker F, Koychev D, Lühmann A, Langer F, Dieckmann K, Bokemeyer C, Oechsle K
ONKOLOGIE. 2013;36(11):663-8.

Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Janjetovic S, Bacher U, Haalck T, Janning M, Bokemeyer C, Fiedler W
ACTA HAEMATOL-BASEL. 2013;129(2):121-125.

Late recurrence of a pineal germinoma 14 years after radiation and chemotherapy: a case report and review of the literature
Janjetovic S, Bokemeyer C, Fiedler W, Frenzel T, Calaminus G, Honecker F
ONKOLOGIE. 2013;36(6):371-3.

Chylothorax in a patient with Hodgkin's lymphoma: a case report and review of the literature
Janjetovic S, Janning M, Daukeva L, Bokemeyer C, Fiedler W
TUMORI . 2013;99(3):e96-9.

Relevant bleeding diathesis due to acquired factor XIII deficiency
Janning M, Holstein K, Spath B, Schnabel C, Bannas P, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2013;33 Suppl 1:S50-4.

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase
Langer F, Spath B, Fischer C, Stolz M, Ayuketang F, Kröger N, Bokemeyer C, Ruf W
BLOOD. 2013;121(12):2324-35.

Marked heterogeneity of ERG expression in large primary prostate cancers.
Minner S, Gärtner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, Heinzer H, Graefen M, Bokemeyer C, Simon R, Sauter G, Schlomm T, Wilczak W
MODERN PATHOL. 2013;26(1):106-116.

Active surveillance is the preferred approach to clinical stage I testicular cancer
Nichols C, Roth B, Albers P, Einhorn L, Foster R, Daneshmand S, Jewett M, Warde P, Sweeney C, Beard C, Powles T, Tyldesley S, So A, Porter C, Olgac S, Fizazi K, Hayes-Lattin B, Grimison P, Toner G, Cathomas R, Bokemeyer C, Kollmannsberger C
J CLIN ONCOL. 2013;31(28):3490-3.

Anxiety and depression in caregivers of terminally ill cancer patients: impact on their perspective of the patients' symptom burden
Oechsle K, Goerth K, Bokemeyer C, Mehnert A
J PALLIAT MED. 2013;16(9):1095-101.

Symptom burden in palliative care patients: perspectives of patients, their family caregivers, and their attending physicians
Oechsle K, Görth K, Bokemeyer C, Mehnert A
SUPPORT CARE CANCER. 2013;21(7):1955-62.

Spättoxizität und Survivorship bei Keimzelltumoren
Oechsle K, Schilling G, Oing C, Bokemeyer C
ONKOLOGE. 2013;19(7):573-581.

Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Oldenburg J, Fosså S, Nuver J, Heidenreich A, Schmoll H, Bokemeyer C, Horwich A, Beyer J, Kataja V
ANN ONCOL. 2013;24 Suppl 6:vi125-32.

Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway
Oliveira Ferrer L, Wellbrock J, Bartsch U, Penas E, Hauschild J, Klokow M, Bokemeyer C, Fiedler W, Schuch G
MOL CANCER. 2013;12(1):144.

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab
Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, Tejpar S
J CLIN ONCOL. 2013;31(30):3764-75.

Molecular characterization of chromosomal band 5p15.33: a recurrent breakpoint region in mantle cell lymphoma involving the TERT-CLPTM1L locus.
Schilling G, Murga-Penas E, Janjetovic S, Oliveira Ferrer L, Balabanov M, Behrmann P, Bokemeyer C, Dierlamm J
LEUKEMIA RES. 2013;37(3):280-286.

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
Seidel C, Busch J, Weikert S, Steffens S, Bokemeyer C, Grünwald V
BRIT J CANCER. 2013;109(12):2998-3004.

Prolonging Survival Through a Personalized Approach in Metastatic Colorectal Cancer
Stein A, Bokemeyer C
J OncoPathol. 2013;1(3):31-41.

Reducing the burden of bone metastases: current concepts and treatment options
von Moos R, Sternberg C, Body J, Bokemeyer C
SUPPORT CARE CANCER. 2013;21(6):1773-83.

Guía clínica sobre el cáncer de testículo de la EAU: actualización de 2011
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M
ACTAS UROL ESP. 2012;36(3):127-45.

[EAU guidelines on testicular cancer: 2011 update].
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M, Urology E
ACTAS UROL ESP. 2012;36(3):127-145.

Role of interleukin 16 in multiple myeloma.
Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander A, Marx A, Uhlig R, Zustin J, Bokemeyer C, Kröger N
JNCI-J NATL CANCER I. 2012;104(13):1005-1020.

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.
Billecke L, Murga-Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Bokemeyer C, Schilling G
ANTICANCER RES. 2012;32(5):2031-2034.

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
Bokemeyer C, Eric V, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne C
EUR J CANCER. 2012;48(10):1466-1475.

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne C
EUR J CANCER. 2012;48(10):1466-75.

The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature
Calabrò F, Albers P, Bokemeyer C, Martin C, Einhorn L, Horwich A, Krege S, Schmoll H, Sternberg C, Daugaard G
EUR UROL. 2012;61(6):1212-21.

The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature.
Calabrò F, Albers P, Bokemeyer C, Martin C, Einhorn L, Horwich A, Krege S, Schmoll H, Sternberg C, Daugaard G
EUR UROL. 2012;61(6):1212-1221.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of: an exploratory analysis of a phase 3 trial
Canon J, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K
MED ONCOL. 2012;29(3):2291-9.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
Canon J, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K
MED ONCOL. 2012;29(3):2291-2299.

Evaluation of BM cytomorphology after allo-SCT in patients with AML.
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuketang Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-1544.

Evaluation of BM cytomorphology after allo-SCT in patients with AML
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-44.

Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target
Clauditz T, Gontarewicz A, Lebok P, Tsourlakis M, Grob T, Münscher A, Sauter G, Bokemeyer C, Knecht R, Wilczak W
ORAL ONCOL. 2012;48(10):991-6.

Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target.
Clauditz T, Gontarewicz A, Lebok P, Tsourlakis M, Grob T, Münscher A, Sauter G, Bokemeyer C, Knecht R, Wilczak W
ORAL ONCOL. 2012;48(10):991-996.

Mycalamide A shows cytotoxic properties and prevents EGF-induced neoplastic transformation through inhibition of nuclear factors
Dyshlovoy S, Fedorov S, Kalinovsky A, Shubina L, Bokemeyer C, Stonik V, Honecker F
MAR DRUGS. 2012;10(6):1212-24.

Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity.
Dyshlovoy S, Naeth I, Venz S, Preukschas M, Sievert H, Jacobsen C, Shubina L, Manuela G, Scharf C, Walther R, Krepstakies M, Priyadarshini P, Hauber J, Fedorov S, Bokemeyer C, Stonik V, Balabanov S, Honecker F
J PROTEOME RES. 2012;11(4):2316-2330.

Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair.
Fenske A, Glaesener S, Bokemeyer C, Thomale J, Dahm-Daphi J, Honecker F, Dartsch D
CANCER LETT. 2012;324(2):171-178.

Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer
Flammiger A, Bayer F, Cirugeda-Kühnert A, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M
APMIS. 2012;120(11):901-8.

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.
Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M
ACTA HAEMATOL-BASEL. 2012;128(2):69-72.

Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
Grob T, Kannengiesser I, Tsourlakis M, Atanackovic D, König A, Vashist Y, Klose H, Marx A, Koops S, Simon R, Izbicki J, Bokemeyer C, Sauter G, Wilczak W
MODERN PATHOL. 2012;25(12):1566-1573.

Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone.
Holstein K, Marx G, Lentz B, Bokemeyer C, Langer F
HAMOSTASEOLOGIE. 2012;32 Suppl 1:48-51.

Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
Kobold S, Luetkens T, Bartels B, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2012;2012:134081.

Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor.
Langer F, Bokemeyer C
HAMOSTASEOLOGIE. 2012;32(2):95-104.

Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial
Lorch A, Kleinhans A, Kramar A, Kollmannsberger C, Hartmann J, Bokemeyer C, Rick O, Beyer J
J CLIN ONCOL. 2012;30(8):800-5.

Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.
Lorch A, Kleinhans A, Kramar A, Kollmannsberger C, Hartmann J, Bokemeyer C, Rick O, Beyer J
J CLIN ONCOL. 2012;30(8):800-805.

PTEN deletion is rare but often homogeneous in gastric cancer.
Mina S, Bohn B, Simon R, Krohn A, Reeh M, Arnold D, Bokemeyer C, Sauter G, Izbicki J, Marx A, Stahl P
J CLIN PATHOL. 2012;65(8):693-698.

Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer
Minner S, De Silva C, Rink M, Dahlem R, Chun F, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W
PATHOLOGY. 2012;44(5):448-52.

Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer.
Minner S, De Silva C, Rink M, Dahlem R, Chun F, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W
PATHOLOGY. 2012;44(5):448-452.

High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers.
Minner S, Lübke A, Kluth M, Bokemeyer C, Jänicke F, Izbicki J, Schlomm T, Sauter G, Wilczak W
HISTOPATHOLOGY. 2012;61(3):445-453.

High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers
Minner S, Luebke A, Kluth M, Bokemeyer C, Jänicke F, Izbicki J, Schlomm T, Sauter G, Wilczak W
HISTOPATHOLOGY. 2012;61(3):445-53.

Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma.
Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, Moch H, Wilczak W, Bokemeyer C, Fisch M, Sauter G, Eichelberg C
CANCER-AM CANCER SOC. 2012;118(5):1268-1275.

Bone metastases in germ cell tumor patients.
Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger L, Oing C, Honecker F
J CANCER RES CLIN. 2012;138(6):947-952.

The metabolite 3-hydroxiglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature.
Oliveira-Ferrer L, Wellbrock J, Balabanov M, Klockow M, Hauschild J, Bokemeyer C, Fiedler W, Ergun S, Schuch G
CANCER LETT. 2012;326(2):161-167.

Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Preukschas M, Hagel C, Schulte A, Riecken K, Lamszus K, Sievert H, Pällmann N, Bokemeyer C, Hauber J, Balabanov M, Balabanov S
PLOS ONE. 2012;7(8):43468.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B, , Bokemeyer C
LANCET ONCOL. 2012;13(12):1250-9.

VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
Schultze A, Ben Batalla I, Riethdorf S, Bubenheim M, Yekebas E, Erbersdobler A, Reichelt U, Effenberger K, Schmidt T, Izbicki J, Bokemeyer C, Pantel K, Fiedler W, Loges S
CLIN EXP METASTAS. 2012;29(8):879-87.

VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.
Schultze A, Ben-Batalla I, Riethdorf S, Bubenheim M, Yekebas E, Erbersdobler A, Reichelt U, Harms-Effenberger K, Schmidt T, Izbicki J, Bokemeyer C, Pantel K, Fiedler W, Loges S
CLIN EXP METASTAS. 2012;29(8):879-887.

Protein-protein-interaction network organization of the hypusine modification system.
Sievert H, Venz S, Platas-Barradas O, Dhople V, Schaletzky M, Nagel C, Balabanov M, Preukschas M, Pällmann N, Bokemeyer C, Brümmendorf T, Pörtner R, Walther R, Duncan K, Hauber J, Balabanov S
MOL CELL PROTEOMICS. 2012;11(11):1289-1305.

Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists.
Spath B, Hansen A, Bokemeyer C, Langer F
PLATELETS. 2012;23(1):60-68.

Kolorektale Tumoren: Individualisierte Therapiestrategien
Stein A, Bokemeyer C
Der Allgemeinarzt. 2012;34(20):38-41.

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Eric V
J CLIN ONCOL. 2012;30(29):3570-3577.

Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro.
Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger H, Brase J, Kuner R, Schlomm T, Sauter G, Sültmann H, Korf U, Bokemeyer C, Walther R, Brümmendorf T, Balabanov S
J PROTEOME RES. 2012;11(4):2452-2466.

Is advanced cancer associated with demoralization and lower global meaning? The role of tumor stage and physical problems in explaining existential distress in cancer patients.
Vehling S, Lehmann C, Oechsle K, Bokemeyer C, Krüll A, Koch-Gromus U, Mehnert A
PSYCHO-ONCOLOGY. 2012;21(1):54-63.

Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M, Braig F, Goethel M, Schulte A, Lamszus K, Bokemeyer C, Binder M
NEOPLASIA. 2012;14(11):1023-1031.

EAU guidelines on testicular cancer: 2011 update
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M
EUR UROL. 2011;60(2):304-19.

EAU guidelines on testicular cancer: 2011 update.
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna M, Urology E
EUR UROL. 2011;60(2):304-319.

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, Kobbe G, Schroeder T, Bokemeyer C, Kröger N
AM J HEMATOL. 2011;86(11):918-922.

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander A, Marx A, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2011;96(10):1512-1520.

Unusual course of myelodysplastic syndrome with presumed familial origin.
Bacher U, Ocheni S, Schafhausen P, Oyekunle A, Dierlamm J, Zander A, Bokemeyer C, Haferlach T, Kröger N
ACTA HAEMATOL-BASEL. 2011;126(4):234-237.

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Balabanov S, Gontarewicz A, von Amsberg G, Raddrizzani L, Balabanov M, Bosotti R, Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake T, Brümmendorf T
PLOS ONE. 2011;6(4):19164.

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel D, Staehler M, Strauss U, Mersmann S, Burock K, Escudier B
ANN ONCOL. 2011;22(8):1812-23.

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel D, Staehler M, Strauss U, Mersmann S, Burock K, Escudier B
ANN ONCOL. 2011;22(8):1812-1823.

Kastrationsrefraktäres Prostatakarzinom - Second-line-Chemotherapie bietet Option auf Überlebensvorteil - Patientenselektion und Nebenwirkungsmanagement - Palliation tumorbedingter Beschwerden
Bokemeyer C
ONKOLOGE. 2011;17(7):1-8.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Bokemeyer C, Bondarenko I, Hartmann J, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P
ANN ONCOL. 2011;22(7):1535-1546.

Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz T, Reiff M, Gravert L, Gnoss A, Tsourlakis M, Münscher A, Sauter G, Bokemeyer C, Knecht R, Wilczak W
PATHOLOGY. 2011;43(5):459-464.

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch J, Bokemeyer C, Schmoll H
ANN ONCOL. 2011;22:1054-1061.

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis
Eichhorst B, Fischer K, Fink A, Elter T, Wendtner C, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M, , Bokemeyer C
BLOOD. 2011;117(6):1817-21.

Supportivtherapie
Feyer P, Bokemeyer C, Panse J, Link H, Piso P
2011. Interdisziplinäre Entscheidungswege in der Onkologie: Diagnose- und Therapiealgorithmen mit Erläuterungen. Deutscher Ärzte-Verlag: 187-194.

Phase I trial of SU14813 in patients with advanced solid malignancies.
Fiedler W, Giaccone G, Lasch P, van der Horst I, Brega N, Courtney R, Abbattista A, Shalinsky D, Bokemeyer C, Boven E
ANN ONCOL. 2011;22(1):195-201.

Prostatakarzinom
Hautmann R, Küfer R, Bokemeyer C, Panse J, Belka C, Hinkelbein W
2011. Interdisziplinäre Entscheidungswege in der Onkologie: Diagnose- und Therapiealgorithmen mit Erläuterungen. Deutscher Ärzte-Verlag: 148-152.

Characterization of Enterobacter cloacae pneumonia: a single-center retrospective analysis
Hennigs J, Baumann H, Schmiedel S, Tennstedt P, Sobottka I, Bokemeyer C, Kluge S, Klose H
LUNG. 2011;189(6):475-83.

Characterization of Enterobacter cloacae pneumonia: a single-center retrospective analysis.
Hennigs J, Baumann H, Schmiedel S, Tennstedt P, Sobottka I, Bokemeyer C, Kluge S, Klose H
LUNG. 2011;189(6):475-483.

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Hennigs J, von Amsberg G, Baumann H, Honecker F, Kluge S, Bokemeyer C, Brümmendorf T, Klose H
BMC PULM MED. 2011;11:30.

Actual and predicted survival time of patients with spinal metastases of lung cancer: evaluation of the robustness of the Tokuhashi score
Hessler C, Vettorazzi E, Madert J, Bokemeyer C, Panse J
SPINE. 2011;36(12):983-9.

Actual and predicted survival time of patients with spinal metastases of lung cancer: evaluation of the robustness of the Tokuhashi score.
Hessler C, Vettorazzi E, Madert J, Bokemeyer C, Panse J
SPINE. 2011;36(12):983-989.

Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Holweger K, Lipp H, Beijnen J, Bokemeyer C, Hartmann J
CANCER CHEMOTH PHARM. 2011;68(3):693-701.

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.
Kobold S, Isernhagen J, Hübel K, Kilic N, Bogner C, Frickhofen N, Bokemeyer C, Fiedler W
BONE MARROW TRANSPL. 2011;46(8):1053-1056.

Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels B, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2011;2011:302145.

Treatment of patients with stage II A/B and advanced nonseminomatous germ cell tumors
Kollmannsberger C, Bokemeyer C
2011. Cancer of the Testis. Springer Berlin Heidelberg: 185-196.

Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update
Koychev D, Oechsle K, Bokemeyer C, Honecker F
INT J ANDROL. 2011;34(4 Pt 2):e266-73.

Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update.
Koychev D, Oechsle K, Bokemeyer C, Honecker F
INT J ANDROL. 2011;34(4 Pt 2):266-273.

Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion.
Laack E, Simon R, Regier M, Andritzky B, Tennstedt P, Habermann C, Verth C, Thoem I, Grob T, Sauter G, Bokemeyer C
J THORAC ONCOL. 2011;6(1):199-202.

Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion
Laack E, Simon R, Regier M, Andritzky B, Tennstedt P, Habermann C, Verth C, Thöm I, Grob T, Sauter G, Bokemeyer C
J THORAC ONCOL. 2011;6(1):199-202.

Akute Blutungen ohne Trauma - Gerinnung checken mit System
Langer F, Holstein K, Bokemeyer C
Der Allgemeinarzt. 2011;33(15):37-40.

Histopathological and molecular features of late relapses in non-seminomas.
Mayer F, Wermann H, Albers P, Stoop H, Gillis A, Hartmann J, Bokemeyer C, Oosterhuis J, Looijenga L, Honecker F
BJU INT. 2011;107(6):936-943.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S, Enodien M, Sirma H, Lübke A, Krohn A, Mayer P, Simon R, Tennstedt P, Müller J, Scholz L, Brase J, Liu A, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T
CLIN CANCER RES. 2011;17(18):5878-5888.

Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
Minner S, Kraetzig F, Tachezy M, Kilic E, Graefen M, Wilczak W, Bokemeyer C, Huland H, Sauter G, Schlomm T
HUM PATHOL. 2011;42(12):1946-1952.

High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, Balabanov S, Kilic E, Wilczak W, Simon R, Sauter G, Schlomm T
PROSTATE. 2011;71(3):281-288.

[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].
Moehler M, Al-Batran S, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer W, Dietrich C, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert H, Galle P, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann J, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz R, Höfler H, Höhler T, Hölscher A, Horneber M, Hübner J, Izbicki J, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause B, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer H, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag P, Schmid R, Schmidberger H, Schmiegel W, Schmoll H, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C, AWMF [
Z GASTROENTEROL. 2011;49(4):461-531.

Treatment of brain metastases from germ cell tumors.
Oechsle K, Bokemeyer C
HEMATOL ONCOL CLIN N. 2011;25(3):605-613.

Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L, Fenner M, Glaesener S, Hartmann J, Chi K, Bokemeyer C, Kollmannsberger C
ANN ONCOL. 2011;22(12):2654-60.

Physical activity, quality of life, and the interest in physical exercise programs in patients undergoing palliative chemotherapy.
Oechsle K, Jensen W, Schmidt T, Reer R, Braumann K, De Wit M, Bokemeyer C
SUPPORT CARE CANCER. 2011;19(5):613-619.

Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller C, Hartmann J, Boehlke I, Bokemeyer C, Group G
EUR UROL. 2011;60(4):850-855.

Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia
Otten J, Schmitz L, Vettorazzi E, Schultze A, Marx A, Simon R, Krauter J, Loges S, Sauter G, Bokemeyer C, Fiedler W
LEUKEMIA. 2011;25(2):375-9.

Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.
Port M, Gläsener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, Honecker F, Abend M
MOL CANCER. 2011;10:52.

Rektumkarzinom
Schlag P, Panse J, Bokemeyer C, Budach W
2011. Interdisziplinäre Entscheidungswege in der Onkologie: Diagnose- und Therapiealgorithmen mit Erläuterungen. Deutscher Ärzte-Verlag: 98-101.

Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.
Schlemmer M, Bauer S, Schütte R, Hartmann J, Bokemeyer C, Hosius C, Reichardt P
EUR J MED RES. 2011;16(5):206-212.

Current standards and new trends in the primary treatment of colorectal cancer.
Stein A, Atanackovic D, Bokemeyer C
EUR J CANCER. 2011;47 Suppl 3:312-314.

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.
Ummanni R, Jost E, Balabanov M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C, Sültmann H, Meyer-Schwesinger C, Brümmendorf T, Balabanov S
MOL CANCER. 2011;10:129.

Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform.
Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, Fälth M, Köllermann J, Walther R, Schlomm T, Sauter G, Bokemeyer C, Sültmann H, Schuppert A, Brümmendorf T, Balabanov S
PLOS ONE. 2011;6(2):16833.

Global meaning and meaning-related life attitudes: exploring their role in predicting depression, anxiety, and demoralization in cancer patients.
Vehling S, Lehmann C, Oechsle K, Bokemeyer C, Krüll A, Koch-Gromus U, Mehnert A
SUPPORT CARE CANCER. 2011;19(4):513-520.

Hodenkarzinom
Winter C, Rabenalt R, Albers P, Bokemeyer C, Panse J, Schmidberger H
2011. Interdisziplinäre Entscheidungswege in der Onkologie: Diagnose- und Therapiealgorithmen mit Erläuterungen. Deutscher Ärzte-Verlag: 152-158.

[Clinical trials and personalized medicine in oncology?].
Arnold D, Bokemeyer C
ONKOLOGIE. 2010;33 Suppl 7(7):25-29.

Studien und personalisierte Medizin in der Onkologie?
Arnold D, Bokemeyer C
ONKOLOGIE. 2010;33 Suppl 7:25-9.

Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
Bokemeyer C
EXPERT OPIN BIOL TH. 2010;10(8):1259-1269.

An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body.
Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K, Hildebrandt Y, Luetkens T, Ihloff A, Kröger N, Bokemeyer C, Atanackovic D
J IMMUNOL METHODS. 2010;358(1-2):56-65.

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander A, Bokemeyer C, Kröger N, Atanackovic D
EXP HEMATOL. 2010;38(10):860-867.

Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome.
Choschzick M, Lassen P, Lebeau A, Marx A, Terracciano L, Heilenkötter U, Jänicke F, Bokemeyer C, Izbicki J, Sauter G, Simon R
MODERN PATHOL. 2010;23(4):603-610.

Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal A, Brüchmann M, Zustin J, Isbarn H, Hellwinkel O, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf T, Izbicki J, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T
CLIN CANCER RES. 2010;16(1):56-64.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A, Plütschow A, Eich H, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn K, Wilhelm M, Debus J, Eble M, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink H, Müller R, Diehl V
NEW ENGL J MED. 2010;363(7):640-652.

Chemotherapie und systemische Therapie bei Lebermetastasen - Kolorektales Karzinom
Folprecht G, Bokemeyer C
2010. Hepatobiliäre und Pankreastumoren. Springer-Verlag GmbH: 387-395.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Heiss M, Murawa P, Koralewski P, Kutarska E, Kolesnik O, Ivanchenko V, Dudnichenko A, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons S
INT J CANCER. 2010;127(9):2209-2221.

Patients with advanced non-seminomatous germ-cell tumour: the art of the start.
Honecker F, Bokemeyer C
ANN ONCOL. 2010;21(8):1569-1571.

[A multi-disciplinary approach to the treatment of germ cell tumors].
Honecker F, Souchon R, Krege S, Bokemeyer C
INTERNIST. 2010;51(11):1382-1387.

Multimodale Therapiekonzepte von Keimzelltumoren
Honecker F, Souchon R, Krege S, Bokemeyer C
INTERNIST. 2010;51(11):1382-7.

Therapie von Hodentumoren: Stadienspezifisch und leitliniengerecht behandeln
Honecker F, Souchon R, Krege S, Bokemeyer C
best pract onkol. 2010;5(1):4-13.

Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Iwanski G, Lee D, En-Gal S, Doan N, Castor B, Vogt M, Toh M, Bokemeyer C, Said J, Thoennissen N, Koeffler H
BRIT J PHARMACOL. 2010;160(4):998-1007.

Isolated limb perfusion with melphalan for the treatment of intractable primary cutaneous diffuse large B-cell lymphoma leg type.
Kobold S, Kilic N, Luetkens T, Bokemeyer C, Fiedler W
ACTA HAEMATOL-BASEL. 2010;123(3):179-181.

Autoantibodies against tumor-related antigens: incidence and biologic significance.
Kobold S, Luetkens T, Cao Y, Bokemeyer C, Atanackovic D
HUM IMMUNOL. 2010;71(7):643-651.

Prognostic and diagnostic value of spontaneous tumor-related antibodies.
Kobold S, Luetkens T, Cao Y, Bokemeyer C, Atanackovic D
Clin Dev Immunol. 2010;2010:721531.

Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Laack H, Sauter G, Bokemeyer C
LUNG CANCER. 2010;69(3):259-264.

High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors.
Lorch A, Rick O, Wündisch T, Hartmann J, Bokemeyer C, Beyer J
J UROLOGY. 2010;184(1):168-173.

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels B, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Kröger N, Bokemeyer C, Brümmendorf T, Atanackovic D
LEUKEMIA RES. 2010;34(12):1647-1655.

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
Marx A, Burandt E, Choschzick M, Simon R, Yekebas E, Kaifi J, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki J
HUM PATHOL. 2010;41(11):1577-1585.

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.
Marx A, Zielinski M, Kowitz C, Dancau A, Thieltges S, Simon R, Choschzick M, Yekebas E, Kaifi J, Mirlacher M, Atanackovic D, Brümmendorf T, Fiedler W, Bokemeyer C, Izbicki J, Sauter G
HISTOPATHOLOGY. 2010;57(3):418-426.

Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation
Mautner V, Nguyen R, Knecht R, Bokemeyer C
ANN ONCOL. 2010;21(11):2294-5.

Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation.
Mautner V, Nguyen R, Knecht R, Bokemeyer C
ANN ONCOL. 2010;21(11):2294-2295.

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2
Mautner V, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich R, Panse J
NEURO-ONCOLOGY. 2010;12(1):14-8.

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord J, Bokemeyer C, Curran D, Gross A, Vermorken J
ANN ONCOL. 2010;21(10):1967-1973.

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brümmendorf T, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T
CLIN CANCER RES. 2010;16(5):1553-1560.

Y chromosome loss is a frequent early event in urothelial bladder cancer.
Minner S, Kilgué A, Stahl P, Weikert S, Rink M, Dahlem R, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W
PATHOLOGY. 2010;42(4):356-359.

Organprotektion in der Tumortherapie - mit Medikamenten vor unerwünschten Wirkungen schützen
Oechsle K, Bokemeyer C
Im Focus Onkologie. 2010;12:43-47.

Unterschätztes Risiko - Kardiotoxizität onkologischer Therapien
Oechsle K, Bokemeyer C
Im Focus Onkologie. 2010;7(8):49-53.

Erratum to: Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
Oechsle K, Bokemeyer C, Honecker F
J CANCER RES CLIN. 2010;136(1):169.

Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
Oechsle K, Bokemeyer C, Honecker F
J CANCER RES CLIN. 2010;136(1):165-167.

Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.
Oechsle K, Lange-Brock V, Krüll A, Bokemeyer C, De Wit M
J CANCER RES CLIN. 2010;136(11):1729-1735.

Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor.
Oechsle K, Lorch A, Honecker F, Kollmannsberger C, Hartmann J, Boehlke I, Beyer J, Bokemeyer C
ONCOLOGY. 2010;78(1):47-53.

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A
EXP MOL PATHOL. 2010;89(2):175-181.

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D, Lindhofer H, Bokemeyer C
CANCER TREAT REV. 2010;36(6):458-467.

Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
Thoem I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen J, Bokemeyer C, Schumacher U, Laack H
CANCER-AM CANCER SOC. 2010;116(17):4114-4121.

Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?
Wellbrock J, Bokemeyer C, Fiedler W
J Oncol. 2010;2010:317068.

Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance.
Wermann H, Stoop H, Gillis A, Honecker F, Gurp v, Ruud J, Ammerpohl O, Richter J, Bokemeyer C, Bokemeyer C, Looijenga L
J PATHOL. 2010;221(4):433-442.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.
Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuketang Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander A, Bacher U
EXP HEMATOL. 2010;38(12):1261-1271.

Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study.
Aapro M, Ludwig H, Bokemeyer C, MacDonald K, Soubeyran P, Turner M, Albrecht T, Abraham I
ANN ONCOL. 2009;20(10):1714-1721.

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander A, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2009;*95*(5):785-793.

Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, Stahl T, Cao Y, Zander A, Bokemeyer C, Kröger N
CLIN CANCER RES. 2009;15(4):1343-1352.

[10 years of the Working Group for Geriatric Oncology of the DGHO/DGG/AIO]
Bokemeyer C
ONKOLOGIE. 2009;32(3):2.

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Bokemeyer C, Bondarenko I, Makhson A, Hartmann J, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos A, Zubel A, Koralewski P
J CLIN ONCOL. 2009;27(5):663-671.

Catumaxomab - Antikörper-basierte intraperitoneale Therapie bei malignem Aszites
Bokemeyer C, Schuch G
Arzneimitteltherapie. 2009;9:264-270.

Gene amplification in ductal carcinoma in situ of the breast.
Burkhardt L, Grob T, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A
BREAST CANCER RES TR. 2009.

Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer.
Choschzick M, Lebeau A, Marx A, Tharun L, Terracciano L, Heilenkötter U, Jänicke F, Bokemeyer C, Simon R, Sauter G, Schwarz J
HUM PATHOL. 2009.

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Eric V, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero A, Mini E, Greil R, Francesco D, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth A, Cunningham D
J CLIN ONCOL. 2009;27(19):3117-3125.

Therapie des metastasierten Kolonkarzinoms
Folprecht G, Bokemeyer C, Weitz J
ONKOLOGE. 2009;15:1223-1234.

Decrease of CD4(+)FOXP3(+) T regulatory cells in the peripheral blood of human subjects undergoing a mental stressor.
Freier E, Weber C, Nowottne U, Horn C, Bartels K, Meyer S, Hildebrandt Y, Luetkens T, Cao Y, Pabst C, Muzzulini J, Schnee B, Brunner-Weinzierl M, Marangolo M, Bokemeyer C, Deter H, Atanackovic D
PSYCHONEUROENDOCRINO. 2009.

NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer.
Gnjatic S, Cao Y, Reichelt U, Yekebas E, Nölker C, Marx A, Erbersdobler A, Nishikawa H, Hildebrandt Y, Bartels K, Horn C, Stahl T, Gout I, Filonenko V, Ling K, Cerundolo V, Luetkens T, Ritter G, Friedrichs K, Leuwer R, Hegewisch-Becker S, Izbicki J, Bokemeyer C, Old L, Atanackovic D
INT J CANCER. 2009.

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Goekkurt E, Al-Batran S, Hartmann J, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J
J CLIN ONCOL. 2009;27(17):2863-2873.

Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.
Haubold K, Rink M, Spath B, Friedrich M, Chun F, Marx G, Amirkhosravi A, Francis J, Bokemeyer C, Eifrig B, Langer F
THROMB HAEMOSTASIS. 2009;101(6):1147-1155.

[Stage-specific treatment for testicular germ cell tumours]
Heidenreich A, Bokemeyer C, Souchon R
UROLOGE. 2009;48(4):377-385.

[Improving care in haemophilia treatment: development of a computerized registry]
Holstein K, Holstein F, Bokemeyer C, Eifrig B
HAMOSTASEOLOGIE. 2009;29(1):27-28.

[Registries and clinical trials in geriatric oncology in Germany]
Honecker F, Bokemeyer C
ONKOLOGIE. 2009;32(3):14-18.

Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
Honecker F, Wermann H, Mayer F, Gillis A, Stoop H, Gurp v, Oechsle K, Oechsle K, Steyerberg E, Hartmann J, Dinjens W, Bokemeyer C, Bokemeyer C, Looijenga L
J CLIN ONCOL. 2009;27(13):2129-2136.

Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D
ONCOLOGIST. 2009;14(12):1242-1251.

Primary NK/T cell lymphoma nasal type of the stomach with skin involvement: a case report
Kobold S, Merz H, Tiemann M, Mahuad C, Bokemeyer C, Koop I, Fiedler W
Rare Tumors. 2009;1(2):173-175.

High-dose chemotherapy in nonseminomatous germ cell cancer.
Kollmannsberger C, Beyer J, Bokemeyer C
BJU INT. 2009;104(9):1398-1403.

Thromboembolische Komplikationen - Prophylaxe und Therapie im Fokus
Langer F, Holstein K, Eifrig B, Bokemeyer C
ONKOLOGE. 2009;15:150-156.

High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors.
Lorch A, Neubauer A, Hackenthal M, Dieing A, Hartmann J, Rick O, Bokemeyer C, Beyer J
ANN ONCOL. 2009.

[Salvage treatment in germ cell tumors : high-dose chemotherapy and the impact of prognostic factors]
Lorch A, Oechsle K, Bokemeyer C, Beyer J
UROLOGE. 2009;48(4):364-371.

Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.
Ludwig H, Aapro M, Bokemeyer C, Macdonald K, Soubeyran P, Turner M, Albrecht T, Abraham I
EUR J CANCER. 2009;45(9):1603-1615.

HER-2 amplification is highly homogenous in gastric cancer.
Marx A, Tharun L, Muth J, Dancau A, Simon R, Yekebas E, Kaifi J, Mirlacher M, Brümmendorf T, Bokemeyer C, Izbicki J, Sauter G
HUM PATHOL. 2009;40(6):769-777.

The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma.
Murga-Penas E, Maria E, Callet-Bauchu E, Ye H, Gazzo S, Schilling G, Schilling G, Vettorazzi E, Vettorazzi E, Salles G, Wlodarska I, Bokemeyer C, Dierlamm J, Dierlamm J
BLOOD. 2009.

Chemotherapie-induzierte Kardiotoxizität
Oechsle K, Bokemeyer C
2009. Supportivtherapie in der Onkologie. Urban & Vogel: 62-71.

Kardiotoxizitäten bei Chemo-Radiotherapie
Oechsle K, Bokemeyer C
ONKOLOGE. 2009;15:157-162.

Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group.
Oechsle K, Bokemeyer C, Hartmann J, Budach W, Trarbach T, Stahl M, Boehlke I, Kollmannsberger C
J CANCER RES CLIN. 2009;135(2):163-172.

Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
Schafhausen P, Dierlamm J, Bokemeyer C, Brümmendorf T, Bacher U, Zander A, Schnittger S, Hochhaus A
CANCER GENET CYTOGEN. 2009;189(1):63-67.

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy).
Schilling G, Bruweleit M, Harbeck N, Thomssen C, Becker K, Hoffmann R, Villena C, Schütte M, Hossfeld D, Bokemeyer C, De Wit M
INVEST NEW DRUG. 2009;27(2):166-172.

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.
Schittenhelm M, Kollmannsberger C, Oechsle K, Harlow A, Morich J, Honecker F, Kurek R, Störkel S, Kanz L, Corless C, Wong K, Bokemeyer C, Heinrich M
MOL CANCER THER. 2009;8(3):481-489.

Adjuvante Therapie des Kolonkarzinoms
Schuch G, Arnold D, Bokemeyer C
ONKOLOGE. 2009;15:1215-1222.

TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
Schultze A, Decker S, Wellbrock J, Horst A, Vohwinkel G, Schuch G, Bokemeyer C, Loges S, Fiedler W
INVEST NEW DRUG. 2009.

A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases.
Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D
EUR J CANCER. 2009;45(10):1748-1756.

Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years.
Thoem I, Rogers C, Andritzky B, Witzel I, Schuch G, Hossfeld D, Bokemeyer C, Laack E
ONKOLOGIE. 2009;32(12):741-746.

Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases.
Thoem I, Schult-Kronefeld O, Burkholder I, Schuch G, Andritzky B, Kastendieck H, Edler L, Wagener C, Bokemeyer C, Schumacher U, Laack H
ANTICANCER RES. 2009;29(1):249-254.

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level <10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B
BMC CANCER. 2009;9:311.

Severe aplastic anaemia following leflunomide therapy.
Wüsthof M, Smirnova A, Bacher U, Kröger N, Zander A, Schuch G, Bokemeyer C
RHEUMATOLOGY. 2009.

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A
ANN ONCOL. 2009;20(12):1964-1970.

HER-2/neu analysis in breast cancer bone metastases.
Zustin J, Boddin K, Tsourlakis M, Burandt E, Mirlacher M, Jänicke F, Izbicki J, Rüther W, Rueger J, Bokemeyer C, Simon R, Sauter G
J CLIN PATHOL. 2009;62(6):542-546.

The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines.
Aapro M, Abraham I, Bokemeyer C, Ludwig H, Macdonald K, Soubeyran P, Turner M
SUPPORT CARE CANCER. 2008;16(2):193-200.

Erythropoietins should be used according to guidelines.
Aapro M, Birgegård G, Bokemeyer C, Cornes P, Foubert J, Gascon P, Glaspy J, Hellström-Lindberg E, Link H, Ludwig H, Osterborg A, Repetto L, Soubeyran P
LANCET ONCOL. 2008;9(5):412-413.

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran S, Hartmann J, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs H, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E
J CLIN ONCOL. 2008;26(9):1435-1442.

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.
Atanackovic D, Altorki N, Cao Y, Ritter E, Ferrara C, Ritter G, Hoffman E, Bokemeyer C, Old L, Gnjatic S
P NATL ACAD SCI USA. 2008;105(5):1650-1655.

The local cytokine and chemokine milieu within malignant effusions.
Atanackovic D, Cao Y, Kim J, Brandl S, Thoem I, Faltz C, Hildebrandt Y, Bartels K, De Weerth A, Hegewisch-Becker S, Hossfeld D, Bokemeyer C
TUMOR BIOL. 2008;29(2):93-104.

CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander A, Fehse B, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2008;93(3):423-430.

Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia.
Ayuketang Ayuk F, Atassi N, Schuch G, Mina S, Fang L, Bokemeyer C, Fehse B, Zander A, Kröger N
LEUKEMIA RES. 2008;32(8):1200-1206.

Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma.
Bartsch G, Eggert K, Soker S, Bokemeyer C, Hautmann R, Schuch G
J UROLOGY. 2008;179(1):326-332.

Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?
Bokemeyer C
J CLIN ONCOL. 2008;26(11):1783-1785.

Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann J, Waller C, Böhlke I, Kollmannsberger C
ANN ONCOL. 2008;19(3):448-453.

[18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial.
De Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, Franzius C, Kliesch S, Schlemmer M, Tatsch K, Heicappell R, Geworski L, Amthauer H, Dohmen B, Schirrmeister H, Cremerius U, Bokemeyer C, Bares R
ANN ONCOL. 2008;19(9):1619-1623.

Comparative proteome, transcriptome, and genome analysis of a gonadal and an extragonadal germ cell tumor cell line.
Glaesener S, Honecker F, Veltman I, Gillis A, Rohlfing T, Streichert T, Otto B, Brümmendorf T, Looijenga L, Bokemeyer C, Balabanov S
J PROTEOME RES. 2008;7(9):3890-3899.

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A, Balabanov S, von Amsberg G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf T
BLOOD. 2008;111(8):4355-4364.

PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A, Balabanov S, von Amsberg G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf T
LEUKEMIA RES. 2008;32(12):1857-1865.

A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC).
Görn M, Habermann C, Anige M, Thoem I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld D, Bokemeyer C, Laack H
ONKOLOGIE. 2008;31(4):185-189.

Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Hartmann J, Pintoffl J, Kröning H, Bokemeyer C, Holtmann M, Höhler T
ONKOLOGIE. 2008;31(5):237-241.

Novel algorithm for more accurate calculation of renal function in adults with cancer.
Holweger K, Lipp H, Dietz K, Hartmann J, Bokemeyer C
ANN PHARMACOTHER. 2008;42(12):1749-1757.

Esophageal squamous cell carcinoma presenting with extensive skin lesions: a case report
Iwanski G, Block A, Keller G, Muench J, Claus S, Fiedler W, Bokemeyer C
J Med Case Rep. 2008;2:115.

Esophageal squamous cell carcinoma presenting with extensive skin lesions: a case report.
Iwanski G, Block A, von Amsberg G, Münch J, Claus S, Fiedler W, Bokemeyer C
J Med Case Rep. 2008;2:115.

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Köhne C, De Greve J, Hartmann J, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke H, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E
ANN ONCOL. 2008;19(5):920-926.

Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Kollmannsberger C, Bokemeyer C
Curr Opin Support Palliat Care. 2008;2(3):167-172.

Pharmacotherapy of relapsed metastatic testicular cancer.
Kollmannsberger C, Honecker F, Bokemeyer C
EXPERT OPIN PHARMACO. 2008;9(13):2259-2272.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, Mulder D, Pieter H, Maria D, de Wit M, de Wit R, Derigs H, Dieckmann K, Dieing A, Droz J, Fenner M, Fizazi K, Flechon A, Fosså S, Muro D, Garcia X, Gauler T, Geczi L, Gerl A, Germa-Lluch J, Gillessen S, Hartmann J, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones W, Kisbenedek L, Klepp O, Kliesch S, Koehrmann K, Kollmannsberger C, Kuczyk M, Laguna P, Galvis O, Loy V, Mason M, Mead G, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof G, Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz H, Schmidberger H, Schmoll H, Schrader M, Sedlmayer F, Skakkebaek N, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H
EUR UROL. 2008;53(3):478-496.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, Mulder D, Pieter H, Maria D, de Wit M, de Wit R, Derigs H, Dieckmann K, Dieing A, Droz J, Fenner M, Fizazi K, Flechon A, Fosså S, Muro D, Garcia X, Gauler T, Geczi L, Gerl A, Germa-Lluch J, Gillessen S, Hartmann J, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones W, Kisbenedek L, Klepp O, Kliesch S, Koehrmann K, Kollmannsberger C, Kuczyk M, Laguna P, Galvis O, Loy V, Mason M, Mead G, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof G, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz H, Schmidberger H, Schmoll H, Schrader M, Sedlmayer F, Skakkebaek N, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H
EUR UROL. 2008;53(3):497-513.

[Haemostatic aspects in clinical oncology]
Langer F, Holstein K, Eifrig B, Bokemeyer C
HAMOSTASEOLOGIE. 2008;28(5):472-480.

Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.
Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, Brümmendorf T, Dierlamm J, Bokemeyer C, Eifrig B
ANN HEMATOL. 2008;87(6):451-457.

[18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, Kliesch S, Mueller S, Krege S, Heicappell R, Bares R, Bokemeyer C, De Wit M
J CLIN ONCOL. 2008;26(36):5930-5935.

Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy.
Oechsle K, Kollmannsberger C, Honecker F, Boehlke I, Bokemeyer C
EUR J CANCER. 2008;44(12):1663-1669.

Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I, Schuch G
J EXP CLIN CANC RES. 2008;27:86.

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D
BRIT J CANCER. 2008;99(6):930-938.

Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Peschel C, Hartmann J, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo M, Hofheinz R
LUNG CANCER. 2008;60(3):374-380.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller A, Loeffler M
LANCET ONCOL. 2008;9(2):105-116.

Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C, Beyer J, Bokemeyer C, Hartmann J, Rick O
EUR J CANCER. 2008;44(2):237-243.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón J, Simon-Perez J, Gutierrez N, Fiedler W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Murga-Penas E, Dierlamm J, Ayuketang Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Miguel J, Nagler A, Kröger N
LEUKEMIA. 2008;22(6):1250-1255.

Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M, Zanger U, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M
J CLIN ONCOL. 2008;26(13):2131-2138.

Stem cell factor as a novel diagnostic marker for early malignant germ cells.
Stoop H, Honecker F, van de Geijn G, Gillis A, Cools M, de Boer M, Bokemeyer C, Wolffenbuttel K, Drop S, de Krijger R, Dennis N, Summersgill B, McIntyre A, Shipley J, Oosterhuis J, Looijenga L
J PATHOL. 2008;216(1):43-54.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H, Cupissol D, Frederic P, Benasso M, Vynnychenko I, Dominique D, Bokemeyer C, Schueler A, Amellal N, Hitt R
NEW ENGL J MED. 2008;359(11):1116-1127.

Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative.
Wellbrock J, Schultze A, Schafhausen P, Otterstetter S, Dierlamm J, Bokemeyer C, Brümmendorf T, Fiedler W, Loges S
BRIT J HAEMATOL. 2008;142(1):115-118.

Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care.
Aapro M, Abraham I, MacDonald K, Soubeyran P, Foubert J, Bokemeyer C, Muenzberg M, Joanna V, Turner M
SUPPORT CARE CANCER. 2007;15(11):1325-1329.

[Molecular biology studies of late recurrence of testicular cancers]
Albers P, Honecker F, Rüschoff J, Sauter G, Müller S, Büttner R, Bokemeyer C
UROLOGE. 2007;46(9):1185-1186.

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld D, Zander A, Jungbluth A, Old L, Bokemeyer C, Kröger N
BLOOD. 2007;109(3):1103-1112.

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, Copland M, Brassat U, Priemer M, Hauber I, Wilhelm T, Schwarz G, Kanz L, Bokemeyer C, Hauber J, Holyoake T, Nordheim A, Brümmendorf T
BLOOD. 2007;109(4):1701-1711.

[Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma]
Bartsch G, Eggert K, Soker S, Fiedler W, Laack E, Volkmer B, Gschwend J, Bokemeyer C, Hautmann R, Schuch G
UROLOGE. 2007;46(9):1289-1290.

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Bokemeyer C, Aapro M, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P
EUR J CANCER. 2007;43(2):258-270.

A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.
Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann J
ANTICANCER RES. 2007;27(4):2845-2848.

Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann J, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk M, Bokemeyer C
J CLIN ONCOL. 2007;25(36):5742-5747.

Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
Hartmann J, Pintoffl J, Al-Batran S, Quietzsch D, Meisinger I, Horger M, Nehls O, Bokemeyer C, Königsrainer A, Jäger E, Kanz L
ONKOLOGIE. 2007;30(5):235-240.

Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M, Ganser A, Bokemeyer C
SEMIN HEMATOL. 2007;44(3):148-156.

A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Laack E, Thoem I, Krüll A, Engel-Riedel W, Müller T, Meissner C, Dürk H, Fischer J, Gütz S, Kortsik C, Elbers M, Schuch G, Andritzky B, Görn M, Burkholder I, Edler L, Hossfeld D, Bokemeyer C
LUNG CANCER. 2007;57(2):181-186.

Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
Langer F, Chun F, Amirkhosravi A, Friedrich M, Leuenroth S, Eifrig B, Bokemeyer C, Francis J
THROMB HAEMOSTASIS. 2007;97(3):464-470.

Aprotinin-associated hemolytic thrombotic microangiopathy in a patient with acute myelogenous leukemia (AML) and systemic coagulopathy.
Langer F, Steinmetz O, Marx G, Amirkhosravi A, Eifrig B, Bokemeyer C, Brümmendorf T
AM J HEMATOL. 2007;82(12):1122-1124.

Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.
Loges S, Butzal M, Wellbrock J, Schweizer M, Fischer U, Bokemeyer C, Hossfeld D, Schuch G, Fiedler W
BIOCHEM BIOPH RES CO. 2007;357(4):1016-1020.

Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis.
Loges S, Clausen H, Reichelt U, Bubenheim M, Erbersdobler A, Schurr P, Yekebas E, Schuch G, Izbicki J, Pantel K, Bokemeyer C, Fiedler W
CLIN CANCER RES. 2007;13(1):76-80.

Germ-cell tumors.
Lorch A, Beyer J, Bokemeyer C
NEW ENGL J MED. 2007;357(17):1772-1774.

Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Lorch A, Kollmannsberger C, Hartmann J, Metzner B, Schmidt-Wolf I, Berdel W, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O
J CLIN ONCOL. 2007;25(19):2778-2784.

Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S, Hartmann U, Mayer F, Balabanov S, Hartmann J, Brümmendorf T, Bokemeyer C
INVEST NEW DRUG. 2007;25(6):519-524.

The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas.
Murga-Penas E, Eva M, Callet-Bauchu E, Ye H, Albert N, Albert N, Copie-Bergman C, Gazzo S, Berger F, Bokemeyer C, Bokemeyer C, Dierlamm J, Dierlamm J
HAEMATOLOGICA. 2007;92(3):405-409.

An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Oechsle K, Honecker F, Kollmannsberger C, Rick O, Grünwald V, Mayer F, Hartmann J, Bokemeyer C
ANTI-CANCER DRUG. 2007;18(3):273-276.

Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine.
Reichmann U, Bokemeyer C, Wallwiener D, Bamberg M, Huober J
ANN ONCOL. 2007;18(12):1981-1984.

Lectin histochemistry of metastatic adenocarcinomas of the lung.
Thoem I, Schult-Kronefeld O, Burkholder I, Goern M, Andritzky B, Blonski K, Kugler C, Edler L, Bokemeyer C, Schumacher U, Laack E
LUNG CANCER. 2007;56(3):391-397.

Tolerance to chemotherapy in elderly patients with cancer.
Wedding U, Honecker F, Bokemeyer C, Pientka L, Höffken K
Cancer Control. 2007;14(1):44-56.

Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
Welz S, Hehr T, Kollmannsberger C, Bokemeyer C, Belka C, Budach W
INT J RADIAT ONCOL. 2007;69(5):1429-1435.

Acute psychological stress alerts the adaptive immune response: stress-induced mobilization of effector T cells
Atanackovic D, Schnee B, Schuch G, Faltz C, Schulze J, Weber C, Schafhausen P, Bartels K, Bokemeyer C, Brunner-Weinzierl M, Deter H
J NEUROIMMUNOL. 2006;176(1-2):141-52.

An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
Hartmann J, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C
INVEST NEW DRUG. 2006;24(3):249-53.

Germ cell lineage differentiation in non-seminomatous germ cell tumours
Honecker F, Stoop H, Mayer F, Bokemeyer C, Castrillon D, Lau Y, Looijenga L, Oosterhuis J
J PATHOL. 2006;208(3):395-400.

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C
ANN ONCOL. 2006;17(6):1007-13.

Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone
Oechsle K, Müller M, Hartmann J, Kanz L, Bokemeyer C
ONKOLOGIE. 2006;29(12):557-61.

Guidelines on testicular cancer
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A, Klepp O, Laguna M, Pizzocaro G
EUR UROL. 2005;48(6):885-94.

Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey
Barrett-Lee P, Bokemeyer C, Gascón P, Nortier J, Schneider M, Schrijvers D, Van Belle S
ONCOLOGIST. 2005;10(9):743-57.

FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals
Becherer A, De Santis M, Karanikas G, Szabó M, Bokemeyer C, Dohmen B, Pont J, Dudczak R, Dittrich C, Kletter K
EUR J RADIOL. 2005;54(2):284-8.

Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial
Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann J
J AM SOC NEPHROL. 2005;16(2):452-8.

Cancer-related anemia: pathogenesis, prevalence and treatment
Birgegård G, Aapro M, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers D, Shasha D, Van Belle S
ONCOLOGY. 2005;68 Suppl 1:3-11.

New guidelines on anaemia management in patients with cancer: How do these affect clinical practice?
Birgegård G, Bokemeyer C
ONCOLOGY. 2005;69 Suppl 2:17-21.

Anaemia in cancer patients: pathophysiology, incidence and treatment
Bokemeyer C, Oechsle K, Hartmann J
EUR J CLIN INVEST. 2005;35 Suppl 3:26-31.

Passive Immuntherapie mit monoklonalen Antikörpern
Bokemeyer C, Panse J
ONKOLOGIE. 2005;28 Suppl 4:9-13.

Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors
Hartmann J, Rick O, Oechsle K, Kuczyk M, Gauler T, Schöffski P, Schleicher J, Mayer F, Teichmann R, Kanz L, Bokemeyer C
ANN SURG. 2005;242(2):260-6.

Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib
Hartmann U, Balabanov S, Ziegler P, Fellenberg J, van der Kuip H, Duyster J, Lipp H, Bokemeyer C, Kanz L, Brümmendorf T
EXP HEMATOL. 2005;33(5):542-9.

Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge
Holweger K, Bokemeyer C, Lipp H
J CANCER RES CLIN. 2005;131(9):559-67.

Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels
Horstmann M, Merseburger A, von der Heyde E, Serth J, Wegener G, Mengel M, Feil G, Hennenlotter J, Nagele U, Anastasiadis A, Bokemeyer C, Stenzl A, Kuczyk M
J CANCER RES CLIN. 2005;131(11):715-22.

Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPY
Kersemaekers A, Honecker F, Stoop H, Cools M, Molier M, Wolffenbuttel K, Bokemeyer C, Li Y, Lau Y, Oosterhuis J, Looijenga L
HUM PATHOL. 2005;36(5):512-21.

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986
Köhne C, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz M, Lorenz M, Reichardt P, Rückle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler H, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Müller L, Genicot B, Anak O, Nordlinger B
J CLIN ONCOL. 2005;23(22):4856-65.

Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO
Kollmannsberger C, Budach W, Stahl M, Schleucher N, Hehr T, Wilke H, Schleicher J, Vanhoefer U, Jehle E, Oechsle K, Trarbach T, Boehlke I, Kanz L, Hartmann J, Bokemeyer C
ANN ONCOL. 2005;16(8):1326-33.

Impact of tumor size on the long-term survival of patients with early stage renal cell cancer
Kuczyk M, Wegener G, Merseburger A, Anastasiadis A, Machtens S, Zumbrägel A, Hartmann J, Bokemeyer C, Jonas U, Stenzl A
WORLD J UROL. 2005;23(1):50-4.

Wirksamkeit und Toxizität der Taxane
Lipp H, Bokemeyer C
Pharmazie in unserer Zeit. 2005;34(2):128-37.

Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines
Mayer F, Mueller S, Malenke E, Kuczyk M, Hartmann J, Bokemeyer C
INVEST NEW DRUG. 2005;23(3):205-11.

Differentiation and development of human female germ cells during prenatal gonadogenesis: an immunohistochemical study
Stoop H, Honecker F, Cools M, de Krijger R, Bokemeyer C, Looijenga L
HUM REPROD. 2005;20(6):1466-76.

Kompressionssyndrome
Wierecky J, Bokemeyer C
INTERNIST. 2005;46(1):9-18.

Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer
Wierecky J, Kollmannsberger C, Boehlke I, Kuczyk M, Schleicher J, Schleucher N, Metzner B, Kanz L, Hartmann J, Bokemeyer C
J CANCER RES CLIN. 2005;131(4):255-60.

Chemotherapie von Keimzelltumoren
Beyer J, Bokemeyer C
UROLOGE. 2004;43(12):1507-13.

2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial
De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen B, Dittrich C, Pont J
J CLIN ONCOL. 2004;22(6):1034-9.

Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil
Hartmann J, Oechsle K, Jäger E, Reis H, Haag C, Niederle N, Wilke H, Pflüger K, Batran S, Büchele T, Hofheinz R, Kanz L, Bokemeyer C
ANTI-CANCER DRUG. 2004;15(5):473-7.

Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
Hofheinz R, Hartmann J, Willer A, Oechsle K, Hartung G, Gnad U, Saussele S, Kreil S, Bokemeyer C, Hehlmann R, Hochhaus A
BRIT J CANCER. 2004;91(5):834-8.

The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management
Pfannenberg A, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen B, Bares R, Hartmann J, Vonthein R, Claussen C
WORLD J UROL. 2004;22(2):132-9.

[ ¹⁸F]FDG-PET, CT/MRT und Tumormarker als prädiktive Indikatoren für das Ansprechen unter Hochdosis-Chemotherapie bei Patienten mit metastasierten Keimzelltumoren
Pfannenberg A, Oechsle K, Kollmannsberger C, Dohmen B, Bokemeyer C, Bares R, Vontheim R, Claussen C
ROFO-FORTSCHR RONTG. 2004;176(1):76-84.

Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas
Hartmann J, Oechsle K, Mayer F, Kanz L, Bokemeyer C
ANTICANCER RES. 2003;23(2C):1899-901.

Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study
Hartmann J, Oechsle K, Quietzsch D, Wein A, Hofheinz R, Honecker F, Nehls O, Köhne C, Käfer G, Kanz L, Bokemeyer C
BRIT J CANCER. 2003;89(11):2051-6.

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma
Reichardt P, Oechsle K, Pink D, Bokemeyer C, Schneller F, Issels R, Kanz L, Hartmann J
INVEST NEW DRUG. 2003;21(4):481-6.

Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET
Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen B, Pfannenberg A, Claussen C, Bares R, Kanz L
BRIT J CANCER. 2002;86(4):506-11.

Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer
Bokemeyer C, Oechsle K, Hartmann J, Schöffski P, Schleucher N, Metzner B, Schleicher J, Kanz L
BRIT J CANCER. 2002;87(10):1066-71.

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma
Kollmannsberger C, Oechsle K, Dohmen B, Pfannenberg A, Bares R, Claussen C, Kanz L, Bokemeyer C
CANCER-AM CANCER SOC. 2002;94(9):2353-62.

Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma
De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen B, Dittrich C, Pont J
J CLIN ONCOL. 2001;19(17):3740-4.

Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell lines
Verbeek W, Bokemeyer C, Falk H, Schmoll H
J CANCER RES CLIN. 1988;114(6):553-8.

Targeting of neoglycoprotein-drug conjugates to cultured human embryonal carcinoma cells
Gabius H, Bokemeyer C, Hellmann T, Schmoll H
J CANCER RES CLIN. 1987;113(2):126-30.

Letzte Aktualisierung aus dem FIS: 18.08.2019 - 00:35 Uhr